{"title": "PDF", "author": "PDF", "url": "https://hartfordhospital.org/File%20Library/Unassigned/NicolauScholarship.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Dr. David Nicolau's Scholarship 11/7/11 1 PUBLICATIONS 1. Nicolau DP, Weart 2. Nicolau DP, Davis SK. Carbonated Annals Pharmacotherapy 1990;24:840. 3. Nicolau West TE. Thalidomide: Treatment of Severe Recurrent Aphthous Stomatitis in Patients 6. Uber WE, Crumbley AJ, Strange C. Amiodarone-Cyclosporine Interaction in a Cardiac Transplant Patient. Journal of Heart and Lung Transplantation 1992;11:564-568. 8. Nicolau DP, Hogan KR. National Survey of Mesna Use for the Prevention of Cyclophosphamide-Induced Hemorrhagic Cystitis in Bone Marrow Transplant Patients. 1992;67:611-612. 9. Nicolau DP, Nightingale CH, Quintiliani 1992;27:675-684. 10. Belliveau PP, Nicolau DP. Antibiotic Efficacy Review. Pharmacy Practice News September 1992. Errata: October 1992; November 1992. 11. Belliveau PP, Nicolau DP. Antibiotic Efficacy Review. General Surgery & Laparoscopy News September 1992. Errata: October 1992. Dr. David Nicolau's Titers by Low-Dose Aspirin in Experimental Aortic Valve Endocarditis. Infection JW, Pharmacokinetics of Minocycline and Vancomycin in Rabbits. Laboratory Animal Science Drug Utilization Evaluation of Imipenem/Cilastatin Dosing in Patients with Renal Human Activity of a Low-Dose Regimen Insuficiencia Renal. Annals Pharmacotherapy (Spanish) 1994;2:60. Optimal the Minimum Inhibitory Concentrations of Ceftibuten and Cefaclor in Experimental Intra-Abdominal Infections. DP, Onyeji CO, Nightingale CH. Caution in the Use Commercial Serum. Laboratory Animal Science 1994;44:100. 24. Nicolau DP, White RL, Friedrich LV, Kays MB. Burn Care Economics: An Analysis with an Emphasis on the Use of Parenteral Antibiotics. Journal of Burn Care & Rehabilitation 1994;15:244-250. 25. CH, Swartz MN, eds. Current Clinical Topics in Infectious Diseases. 14 Vol. Cambridge, MA: Blackwell Scientific, 1994;14:252-265. 26. Nicolau DP, Quintiliani R. Quintiliani R. Minocycline versus Vancomycin for the Treatment of Experimental Oxacillin-Resistant Staphylococcus aureus Endocarditis. Antimicrobial Interactions: A Review an Emphasis on the Macrolide Antibiotics. Continuing Education Monograph (1st Edition). Greenwich, CT: Clinical Against Common Pathogens of Intraabdominal Infection. American Journal of Hospital Pharmacy 1994;51:1782-1787. 30. Nicolau DP, Crowe H, Nightingale CH, Fluconazole. Sequential Intravenous/Oral Ciprofloxacin. Infectious Diseases of Azithromycin Into Inflammatory and Noninflammatory Blister Fluid. Antimicrobial Agents with that of Clarithromycin Against Mycobacterium avium-intracellulare Complex in Human Macrophages. Antibiotic Therapy in the Hospital Setting: Cost Containment by Switching from Parenteral to Oral Therapy. Journal of American Medical Association Southeast Asia 1994;(Suppl. 3)10:373-378. 35. Nicolau DP. What Degree of Resistance is Still Acceptable? Resistance in Gram-positive bacteria: implications for the economics of treatment. Oxfordshire, UK: MEDICINE Publishing Foundation, Symposium Series 36, Kinetics of Aspirin in Female New Zealand White Rabbits. Laboratory Animal Science 1995;45:67-69. 37. Nicolau DP, Freeman CD, Belliveau PP, Experience with Once-Daily Aminoglycoside Program Administered to 2,184 Adult Patients. 1995;39:650-655. Infusion Therapy DP, Quintiliani Nightingale Dynamics for the Clinician. In Cunha B, ed. Medical Clinics of North America. Philadelphia, PA: W.B. Saunders, 1995;79:477-495. Dr. David Nicolau's Scholarship The Effect of Fleroxacin on the of Multiple-Dose Cephalosporin-Metronidazole Combinations in the Management of Intra-Abdominal Infections. Diagnostic Microbiology and Infectious Disease 1995;22:189-194. 44. Patel Nicolau DP, Quintiliani R, Nightingale CH. Pharmacokinetics of Cefotaxime in Healthy Volunteers and Patients. Diagnostic Microbiology and Infectious Disease 1995;22:49-55. 45. Nicolau DP, Nightingale CH. Drug-Drug Interactions: A Review an Emphasis on the Macrolide Antibiotics. Continuing Education Monograph (2nd Edition). Greenwich, Quintiliani R. Influence of Aspirin on the Development and Treatment of Experimental S. aureus Endocarditis. Antimicrobial Agents a Once-Daily Aminoglycoside Program in a Large Community-Teaching Hospital. Hospital Nie L, 6 Quintiliani R. Bioavailability of Fluconazole Administered Via a Feeding Tube in Intensive Care Unit Patients. Journal Antimicrobial Chemotherapy 1995;36:395-401. 51. Marangos HP, Absorption of Ciprofloxacin in Patients With Diabetic Gastroparesis. Antimicrobial Agents & 52. Patel KB, CH, Daily? Drugs & Therapy Perspectives 1995;6:10. 54. Nicolau DP. Attributes of Oral Cephalosporins For Use in Switch Therapy. Pharmacy Times 1995;(Suppl. to October):7-12. 55. Nicolau DP, Crowe R. Interaction of Rifampin and Fluconazole in Intensive Care Unit Patients. Annals Pharmacotherapy 1995;29:994-996. 56. ME, Patel KB, of the Bactericidal Activities of Ofloxacin and Ciprofloxacin Alone or in Combination with Ceftazidime and Piperacillin Against Clinical Strains of Pseudomonas aeruginosa. Antimicrobial CH. Postpartum Endometritis. Journal of Infectious Disease Pharmacotherapy 1995;3:11-18. Dr. David P, Quintiliani R. Relevance Vancomycin Resistance Experimental Activity: Continuous Infusion versus Intermittent 1996;40:61-64. 62. Quintiliani Attention to Therapy with Ceftizoxime, Cefotaxime, and Ceftriaxone. Infectious Diseases Attributes of Oral Cephalosporins for Use in Switch Therapy. American Journal of Managed Care 1996;(Suppl. February):S6-S16. against Pathogens Associated With Community- and American Health-System 1996;53:1024-1027. 65. Aminoglycoside Dosing: Impact on Requests and Costs for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 1996;18:263-266. 66. Quintiliani R, Nightingale Nightingale CH. Swine Model of Continuous Arteriovenous Hemofiltration.. Laboratory Animal Science 1996;46:355-357. Dr. David Nicolau's and 69. Klepser ME, Zhu Nightingale CH. Interactions: An Emphasis the Macrolide Antibiotics. Physicians On-Line. Continuing Medical Education Monograph (3rd Edition). Greenwich, CT: Clinical Communications, 1996. 72. Hitt CM, Nightingale CH, Quintiliani R, Nicolau DP. Ambulatory Therapy Diseases. In Kelley WN, DuPont HL, Glick JH, Harris ED, Hathaway DR, Hudson LD, Humes HD, Paty DW, Yamada T, eds. Textbook of Internal Medicine. 3rd Edition. Philadelphia, PA: J. B. Lippincott, 1996:1856-1858. A Infectious Diseases in Clinical Practice 1996;5:432-434. 74. Nicolau DP, Feng YJ, Wu AHB, Bernstein SP, Nightingale CH. Evaluation of Myoglobin Clearance During Continuous Hemofiltration in a Swine Model of Acute Renal Failure. International Journal of Artificial Organs 1996;19:578-581. 75. Patel KB, Nicolau DP, CH, Quintiliani R. Influence of Ticlopidine on the Development of Experimental Staphylococcus aureus Endocarditis. In Berkarda B, ed. 10th Mediterranean Congress of Chemotherapy. Italy: Monduzzi Editore, Influence of Adjunct Azithromycin Therapy on the Mortality of Experimental Sepsis Due to Pseudomonas aeruginosa. In Berkarda B, ed. 10th Mediterranean Influence of Ticlopidine on the Development of Experimental Staphylococcus aureus Endocarditis. International Journal Antimicrobial Antibiotic Usage. In Johnson JT, Yu VL, eds. Infectious Diseases and Antimicrobial Therapy of the Ears, Nose and Throat. Philadelphia, PA: W.B. Saunders, 1997:48-55. Quintiliani R, Nicolau DP. Streamlining Antibiotic Therapy in Lower Respiratory Tract Infections. Clinical Infectious Diseases 1997;24(Suppl. 2):S231-S237 82. CH. Disposition of Ofloxacin in Female New Zealand White Rabbits. Journal of Veterinary Pharmacology and Therapeutics 8- against Staphylococcus aureus, Streptococcus pneumoniae, and Interval on the Efficacy of Penicillin Containing Regimens in Experimental Enterococcus faecalis Endocarditis. Journal Antimicrobial 1997;7:28. 86. Xuan D, Nicolau DP, Tessier PR, Bow R, Nightingale CH. In Vitro Reduction of Endotoxin Concentrations with the 5S Fragment of Immunoglobulin G. Antimicrobial Agents & Chemotherapy 1997;41:1512-1516. 87. Owens RC Antimicrobial Concentrations on the Mortality of Experimental Pseudomonas aeruginosa In Zinner SH, Young LS, Acar JF, HC, eds. Expanding Indications for the Azithromycin on the Mortality of Experimental Pseudomonas aeruginosa Sepsis. International Journal Antimicrobial Daily i.v. doses Ceftriaxone Versus Continuous Infusion of Cefotaxime. American Journal Health-System Pharmacy Metronidazole for the Treatment of Community-Acquired Intraabdominal Infection and for Chemoprophylaxis Prior to the Treatment of Experimental Enterococcus faecalis and Methicillin-Resistant Staphylococcus aureus Endocarditis. Journal of Infectious and Selected \u00df-Lactams Against 75 Gram-Negative Clinical Isolates. Antimicrobial Administration. Journal of Pharmacy Technology 1997;13:258-262. 98. Patel KB, Nicolau DP, Mechanisms of Action Bacteriostatic Medicine and Ceftriaxone Vancomycin against S. pneumoniae with Variable Penicillin Susceptibilities. Antimicrobial Agents & Chemotherapy 1998;42:991-992. of Ticlopidine on the Treatment of Experimental Staphylococcus aureus Endocarditis. International Journal Antimicrobial Agents 1998;9:227-229. 103. a Bioabsorbable Polymer for the Delivery of Ofloxacin During Dr. David Nicolau's Scholarship 11/7/11 12 Experimental Osteomyelitis DP. Infusion Phlebitis: Relative Incidence Associated with Cefuroxime Administered by Intermittent and Continuous Infusion. Clinical Drug Investigation 1998;15(6):531-535. 106. Nicolau DP, Feng YJ, Wu AHB, CH. Myoglobin Clearance During Continuous Veno-Venous Hemofiltration With or Without Dialysis. International Journal of Artificial Organs 1998;21:205-209. 107. Quintiliani RC Jr. Infectious Diseases Society of America Position Statement on Infectious Diseases Physician and Hospital Pharmacist: Comment and Editorial. Clinical Infectious Diseases 1998;27(1):229. 108. Nicolau DP. Pharmacodynamic Considerations in Oral Cephalosporin Therapy: Implications for Selection and Effectiveness. Infectious Diseases in Clinical Practice 1998;7(2 Suppl.):S81- S85. 110. Nightingale CH. Comparison of the Bactericidal Activities of Intermittent and Continuous Infusion Dosing Regimens of Vancomycin against Methicillin-Resistant eds. Antimicrobial Therapy and Vaccines. First Edition. Baltimore, MD: Williams & Wilkins, 1998:621-638. Nicolau's Scholarship 11/7/11 13 113. Nicolau DP. Optimizing Antimicrobial Therapy and Emerging Pathogens. American Journal of Managed Care 1998;4(Supplement - PG, Quintiliani R, DP. Continuous Vs. Intermittent Infusion of Cefuroxime for the Therapy of Community-Acquired Pneumonia. Infectious Diseases in Practice KQ, DP. Editorial Review. PharmacoEconomics: Infectious Diseases 1998; of Continuous and Intermittent Ceftazidime in Intensive Care Unit Patients with Nosocomial Pneumonia. Infectious Diseases in Clinical Practice 1999; 8:45-49. 119. Lacy MK, Lu W, Against pneumoniae in an In Vitro Model of Infection. Antimicrobial Agents & Chemotherapy 1999; 43:672-677. Activities of Gentamicin and Vancomycin Against Enterococcus Faecalis Resistant to the Drugs: An In Vitro Study with Human Neutrophils. International Journal Beneficial Effect of Combination Antiplatelet Therapy on the Development of Experimental S. aureus Endocarditis. International Journal Antimicrobial Agents 1999; 11:159-161. 122. R. Pharmacokinetic and Economic Evaluation of Piperacillin/Tazobactam Administered either as a Continuous or Intermittent Dr. David Nicolau's Scholarship 11/7/11 14 Infusion with Once-Daily Gentamicin. Infectious Diseases in Clinical Practice 1999;8:195-200. 123. Keung Effect in Subjects Seropositive for the Human Immunodeficiency Virus. Antimicrobial Agents & Rabbit. Journal of 1999;51(4)393-396. 125. Grant EM, Nicolau DP, Nightingale CH, Infusion Connecticut Medicine 1999;63:275-277. 126. Ambrose PG, Cefepime with Ceftazidime in Intensive Care Unit Patients with Hospital-Acquired Pneumonia. Infectious Diseases in Clinical Practice 1999;8:245-251. Nicolau DP, Onyeji of Intermittent and Infusion Cefepime Alone and in Combination with Once-Daily Tobramycin Against Pseudomonas Aeruginosa in an In Vitro Infection Chemotherapy 1999;45:284-295. CO, against Streptococcus Pneumoniae in a Mouse Model of Experimental Septicemia. International Journal Antimicrobial Agents 1999;12:107-114. 129. Nicolau DP, Pharmacokinetics and Pharmacodynamics of Continuous and Intermittent Ceftazidime During the Treatment of Nosocomial Pneumonia. Clinical Drug Investigation 1999;18(2):133-139. 130. Treatment and Outcomes in 10 Hospitals in the United States. Pharmacy & Therapeutics 1999;24(8):390-396. Dr. David Nicolau's Scholarship 11/7/11 Patients Mycobacterium avium Complex Treatment of Systemic Vancomycin- and Gentamicin-Resistant Enterococcus Faecalis Infection in Mice. McNabb JC, Nicolau DP. Streptococcus pneumoniae in a Murine Model. Journal BF, Nicolau DP. Using Pharmacodynamic/Pharmacokinetic Surrogate markers in Clinical Practice: Optimizing Antibiotic Therapy in Respiratory Tract Infections. American Journal of Health-System Pharmacy R. Oral Bioavailability and Pharmacokinetics of Trovafloxacin in Patients with AIDS. Antimicrobial Nicolau DP, in Treatment of Mucoid Pseudomonas aeruginosa Pneumonia Murine 139. Nightingale Quintiliani R. Influence Azithromycin on the Outcome of Experimental Pseudomonas aeruginosa pneumonia. Journal of Infectious Disease Pharmacotherapy and Pharmacoeconomic Evaluation of Ticarcillin/Clavulanate Administered either as Continuous or Intermittent Infusion with Once-Daily Gentamicin. Infectious Diseases in Clinical Practice 1999;8(9):449-455. 142. Freeman CD, Nicolau DP. Community-Acquired Pneumonia in Long-Term Care: The Other Pharmacist 1999;11:1259-1273. 143. Grant EM, Nicolau DP. Pharmacodynamic Considerations in the Selection of Antibiotics for Respiratory Tract Infections: Focus on the Fluoroquinolones. Antibiotics for Clinicians 1999;3(Suppl 1):21-28. 144. Lacy MK, Quintiliani R, CH. Comparison of Mycobacterium avium Complex Prophylaxis in AIDS Patients. Infectious Diseases in Clinical Practice 2000:9;27-32. 146. Nicolau DP. Establishing the Clinical Role of the New Fluoroquinolones. Journal of Infectious Diseases and In Vivo Influence of Adjunct Clarithromycin on the Treatment of Mucoid and Pharmacodynamics of Cefixime: Implications for Clinical Practice. In Adam D, Quintiliani R, eds. Cefixime: A Decade of Clinical Success in Treating Community-Acquired Dr. David Nicolau's Scholarship 11/7/11 17 Bacterial Infections; A Gold Standard Advancing into the New Millennium. Tokyo, meningitidis in Cerebrospinal Fluid and Broth Culture Media. Diagnostic Microbiology and Infectious Disease 2000;36:241-247. 150. Nicolau DP, Meropenem Solution in a Portable, Refrigerated Infusion Pump. American Journal of Health-System Pharmacy 2000;57:992-995. 153. Nicolau DP. The Challenge of Prescribing Treatment for Respiratory Tract Infections. In May Supplement titled Emerging Drug-Resistant Pathogens in Respiratory Tract Infections: Treatment Options. American Journal of Managed Care 2000:6(Suppl. R. Comparison of Vancomycin Pharmacodynamics (1 gram every 12 or 24 hours) against Methicillin-Resistant Staphylococcus. International Journal Antimicrobial Agents 2000;15(1):25-30. 155. Nicolau DP, Ambrose PG. Pharmacodynamics and Monte Carlo Analysis. Respiratory Surveillance Program \"RESP\" Newsletter, August 2000. 156. Xuan D, Lu Hospitalized Patients. International Journal Antimicrobial Agents 2000;15:185-191. 157. McNabb JC, of Leukocyte in Healthy Volunteers versus Dr. David Nicolau's Scholarship 11/7/11 18 Volunteers with AIDS. International Journal Antimicrobial Agents 2000;16:37-43. 158. McNabb EM, Nightingale CH. Cost-Effectiveness in the Use of Antibiotics. Current Clinical Topics in Infectious Diseases 2000;20:24-42. 159. Onyeji CO, Nicolau Bactericidal Activity of Trovafloxacin and Ciprofloxacin, Alone and in Combination with Cefepime against Pseudomonas aeruginosa. Chemotherapy 2000:46(6):383-389. 161. Roberts RB, Chung M, deLencastre H, Hargrave J, Tomasz A, Nicolau DP, Korzeniowski O, Tri-State MRSA Collaborative Study Group. Distribution of Methicillin-Resistant Staphylococcus aureus Among Health Care Facilities in Connecticut, New Jersey and Pennsylvania. Microbial Drug Resistance 2000;6(3):245-251. 162. 2000;35(Suppl. 3):S16-S24. 163. Nicolau DP. Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections. American Journal of Managed Care 2000;6(23)Suppl.- December:S1202-1210. 164. Grant Pharmacology 2001;41:206-209. CH. of Adjunctive Treatment with Combined Cytokines in Mouse Model Multidrug-Resistant Exposure of Moxifloxacin or Levofloxacin Using a Rabbit Tissue cage Model. Antimicrobial Agents & 2001;45(3):794-799. Circulating Tumor Necrosis Factor-Alpha Production During the Progression of Rat Endotoxic Sepsis. Chemotherapy CH. Continuous versus Intermittent Administration of Ceftazidime in Intensive Care Unit Patients with Nosocomial Pneumonia. International Journal Antimicrobial Agents 2001:17(6);497-504. 171. Journal Antimicrobial Agents 2001:17(6);483-489. 172. Mattoes HM, JL, Quintiliani Advantages of Continuous Infusion Beta Lactams. Ochsner Clinic Reports on Serious Hospital Infections Interval Piperacillin/Tazobactam. Journal Antimicrobial Chemotherapy 2001:48;259-267. Dr. David Nicolau's Scholarship 11/7/11 20 175. Predicts Outcome in Minority HIV-Infected Clinic. Clinical Infectious 2001:33(5);700-705. 176. Grant EM, Nicolau DP, Nightingale CH, Quintiliani R. Clinical Considerations Regarding the Administration of Beta-lactam Antibiotics by Continuous Infusion. Journal of Infectious Diseases Pharmacotherapy Pharmacodynamics in and Clinical Practice. New York, NY: Marcel Dekker 2002:125-153. 178. Mattoes HM, Nicolau DP. Revised Guidelines on the Treatment of Community-Acquired Pneumonia: New Recommendations of the American Thoracic Society. Pharmacy Practice News. September 2001:82-87. 179. Capitano B, CH, Quintiliani R, Nicolau for Prophylaxis Treatment of Bacterial Endocarditis in Children. Paediatric Drugs 2001;3(10):703-718. 180. Zhou W, Davis GA, Nicolau DP. Absolute Bioavailability of Fluconazole Suspension in Intensive Care Unit Patients. Journal of Infectious Diseases Pharmacotherapy 2001;5(1):27-35. 181. Xuan by High-Performance Liquid Pharmacodynamic Profiling Levofloxacin and Gatifloxacin Monte Carlo Simulation for Community-Acquired Isolates of Streptococcus pneumoniae. American Journal Ofloxacin Clearance During Continuous Hemofiltration in a Swine Model of Acute Renal Failure. Journal of Infectious Diseases Pharmacotherapy 2001;5(2):21-27. Dr. David Nicolau's Scholarship 11/7/11 PG, Nightingale CH, Quintiliani R. Cefepime in Pneumonia Caused by Pseudomonas aeruginosa. Journal of Infectious Diseases Pharmacotherapy 2001;5(2):43-55. 185. Klepser ME, Lewis RE, Ernst EJ, Petzold CR, Bailey EM, Burgess DS, Methods for Conducting Antifungal Time-Kill Studies. Journal of Infectious Diseases Pharmacotherapy 2001;5(2):29-41. DP. Predicting Antibacterial Dec;29 Suppl 2:11-5. 187. Nicolau DP. Guest Editor - Maximizing Outcomes in Respiratory Tract Infections in the Age of Resistance. Pharmacotherapy Discussion: Maximizing Outcomes in Respiratory Tract Infections in the Age of Resistance. Pharmacotherapy A Population Approach. Pharmacy and Pharmacology 2002;54:71-75. 191. Kim MK, Banevicius MA, DP. Clearance during Continuous Veno-Venous Hemofiltration (CVVH) with or without Dialysis. International Journal of Artificial Organs 2002;25(1):33-9. 192. Grant EM, Kuti JL, Piperacillin/Tazobactam Administered by Continuous versus Intermittent Infusion. Pharmacotherapy 2002;22:471-483. 193. Nicolau DP. Pharmacodynamic Rationale for Infection A):17-23. Dr. David Nicolau's Scholarship 11/7/11 22 194. Tessier PR, Kim MK, Zhou Li C, Ye M, Nightingale CH, Nicolau DP. Pharmacodynamic Assessment of Clarithromycin in Model of Pneumonia. Antimicrobial Agents & Chemotherapy 2002;46(5):1425-1434. 195. Kim MK, International Journal Antimicrobial Agents 2002;19(4):341-8. 197. Kuti JL, Grant EM, Sutherland CA, M, Zhou W, McCarter Y, Nightingale CH, Nicolau DP. Divergence Pseudomonas Piperacillin and Piperacillin/Tazobactam. Journal of Infectious Community-Acquired RTIs: and Capitano to the Treatment of Community-acquired Pneumonia in the Era of Resistance. Pharmacoeconomics 2002;20(8):513-528. 201. Neutropenic Thigh Model. Antimicrobial Agents & Chemotherapy 2002:46(9):2990-2995. 202. Kim MK, Zhou W, Pneumococcal Pneumonia Model. Agents & Chemotherapy 2002;46(10):3185-3192. Dr. David Nicolau's Scholarship 11/7/11 23 203. Nicolau DP. Clinical and Economic Implications of Antimicrobial Resistance for the Management of Community-Acquired Respiratory Tract Infections. Journal Antimicrobial Chemotherapy EM, Nicolau Piperacillin/Tazobactam against Pseudomonas aeruginosa using Monte Carlo Analysis. Diagnostic Microbiology and Infectious Diseases 2002;44(1):51-57. 206. Vivo Techniques for Gatifloxacin against Streptococcus pneumoniae. Journal Pharmacist-Managed Automatic Intravenous to Oral Conversion Program. American Journal Pharmacy 2002;59:2209-2215. 208. Dandekar PK, Nicolau DP. Pharmacodynamic Considerations for the of Oral Cephalosporins in the Treatment of Sinusitis. Otolaryngology, Head and Impact of Managing Methicillin-Resistant Staphylococcus aureus in a Long Term Care Facility. Journal of American Geriatric Society 2003;51(1):10-16. 210. American Journal Microbiology Laboratories: Dr. David Nicolau's Scholarship 11/7/11 24 Survey of Connecticut Hospitals from 1998-2002. Connecticut Medicine 2003;67(3):149-52. 213. Streptococcus pneumoniae in the Thigh Infection Model. Antimicrobial Agents & Chemotherapy 2003;47(5):1630-1635. 214. Maglio DP. Pharmacokinetic Profile of Meropenem 500 mg Every 8 Hours in Plasma and Cantharidin-Induced Skin Blister Fluid. Antimicrobial Agents Maglio Nicolau DP. Production and of Inflammatory Journal Antimicrobial Agents 2003;22(1):77-80. 218. Capitano B, Nicolau DP. Evolving Epidemiology and Cost of Antimicrobial Resistance in Long-term Care Facilities. Journal of the American Medical Directors Association 2003;4(Issue 3 Suppl):S90-S99. 219. Meropenem 220. Nicolau DP. Aminoglycoside Dosing Comment: 2003;November:9. 221. McNabb JJ, Nicolau DP, Stoner JA, Ross J. Patterns of Adherence to Antiretroviral Medications: the Value of Electronic Monitoring. AIDS 2003:17;1763-1767. Dr. David Nicolau's Scholarship 11/7/11 25 222. Kim MK, CH, Nicolau Influence Gender on the of Fleroxacin and Ciprofloxacin with Caffeine. Clinical Methicillin Resistant Staphylococcus aureus in a Murine Thigh Infection Model. Journal Antimicrobial Chemotherapy 2003;52(3):405-11. 224. Li C, Geng Q, Nicolau DP, Nightingale CH. Simultaneous Determination of Ticarcillin and Clavulanate Rabbit Serum and Tissue Cage Fluid (TCF) by Journal of Chromatograph 2003;794(2):227-236. 225. Maglio D, Nicolau DP. Antibiotic Efficacy Review. Infectious Disease Special Edition. McMahon to Design an Optimized Pharmacodynamic Dosing Strategies for Meropenem. Journal of Clinical Zdanowicz MM, by Streptococcus pneumoniae: Epidemiology, Management and Prophylaxis. Continuing Education Monograph, Massachusetts College of Pharmacy & Health 2003;1-20. Analysis of Continuous versus Intermittent Infusion Piperacillin/Tazobactam: A Time Motion Study. American Journal of Health-System Organisms. ESBLs: Pharmacodynamics, Clinical Relevance, Evolution, Prevalence, and Methods for Detection and Reporting. Biomerieux Monograph, 2003;24-32. 230. Novel Lipopeptide of Resistant Gram-Positive Infections. Formulary 2003;38:634-645. Dr. David Kuyumjian AG, Krebs W, McDaniel A, Hogan P, Lubowski TJ. Relation between Fluoroquinolone Use and Changes in Susceptibility to Fluoroquinolones of Selected Pathogens in 10 United States Teaching Hospitals, 1991 through 2000. Clinical Infectious Diseases 2003;37:1643-1648. 232. Perkerson KA, Kuti JL, and Ketolides. Infectious Disease Clinics of North America 2003;17:563-577. 235. Nicolau DP. Optimizing Outcomes with Antimicrobial Therapy Through Pharmacodynamic Profiling. of Infection Analysis Beneficial Pharmacokinetic Interaction Between Cyclosporine and Itraconazole in Renal Transplant Recipients. Transplantation Proceedings 2003;35(8):2873-2877. 237. Nicolau DP, Klepser ME. The Bacterial Revolt: What can be Done About Antibiotic-Resistant Pneumococci? Journal of JL, of a Clinical Pharmacist on Drotrecogin alfa (activated) Outcomes in a Large Community Teaching Hospital. Journal of Infectious Diseases Pharmacotherapy 2003;6(3):55-67. 239. Connecticut Medicine 2004;68(1):11-15. Use Pharmacodynamic Profiles to Optimize Treatment Outcome in Community-Acquired Bacterial Respiratory Tract Infections -Application to Telithromycin. A, Russo R, Barros A Jr., Gajjar DA. Characterization of the Penetration of Garenoxacin into Breast Milk of Lactating Women. Journal of Clinical 2004;44(2):188-92. Study of -Lactams alone and in Combination with -lactamase against International Journal Antimicrobial Agents 2004;23:291-295. 245. Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C, Nicolau DP. Steady State Intrapulmonary Concentrations of Moxifloxacin, Levofloxacin Older Adults. Moxifloxacin and Lining Fluid Concentrations Against Streptococcus pneumoniae. Antimicrobial Agents & Chemotherapy 2004;48(4):1215-1221. 247. Nicolau DP. of a Novel a Novel Class: The Oxazolidinone Antibiotics. Tampa, FL: Innova Institute for Medical 2004:43-54. Lipid versus Liposomal Amphotericin B in the Treatment of Fungal Infections. PharmacoEconomics Dr. David Nicolau's Synergistic Activity Vancomycin and and in Combination with Streptomycin against Enterococcus faecalis with Various Vancomycin Agents 2004;23-343-348. 250. Dandekar of the Pharmacodynamic Profile of Daptomycin against Streptococcus pneumoniae with Varying Susceptibility to Penicillin in a Murine Thigh Infection Model. Chemotherapy 2004;50(1):11-16. 251. Maglio Escherichia coli & Klebsiella isolates in a Large Community Teaching Hospital in Connecticut. Diagnostic Microbiology and Infectious Disease 2004;49:37-39. 254. Maglio D, Ong C, Banevicius MA, Geng Q, CH, Nicolau DP. Determination Extended-Spectrum Beta-Lactamase Producing Various Capitano Potoski1 BA, Byers K, Horowitz M, Venkataramanan R, Paterson DL. Meropenem Administration as a Prolonged Infusion to Treat Gram-negative Central Nervous System Infections. E. coli, K. pneumoniae, A. baumannii and P. aeruginosa from the MYSTIC Surveillance Program: The OPTAMA Program, South America 2002. Diagnostic Microbiology and Infectious Disease 2004;49;109-116. Dr. David Nicolau's a Meropenem Dosing Protocol Based on Pharmacodynamic Concepts in a Large Teaching Hospital. American Journal of Pharmacy Antibiogram (OPTAMA) Program - North America 2002. Antimicrobial Agents & Chemotherapy 2004;48(7):2464-2470. 259. Maglio D, MA, CH, Nicolau DP. Differential Efficacy of Clarithromycin in Lung versus Thigh Infection Models. Chemotherapy 2004;50:63-66. 260. Ong CT, Nicolau DP. Rationale and Utility of Therapeutic Drug Monitoring for the Optimization of Antibiotic Therapy. In Hempel G, ed. Handbook of Analytical Separations: Drug Monitoring (Volume 5). Amsterdam, Netherlands: Elsevier Sciences 2004;195-219. 261. Smith DL, Bauer SM, Nicolau DP. Stability of Refrigerated Meropenem in Normal Saline PVC bags and in an Elastomeric Infusion Device. American Journal of Health-System Pharmacy Against Pseudomonas aeruginosa in Neutropenic and Non-neutropenic Host. International Journal 2004;24:21-27. 263. Pseudomonas aeruginosa Pneumonia in the Neutropenic and Non-Neutropenic 2004;26(8):1187-1198. Dr. Kuti JL, Nicolau DP. Appropriate Antimicrobial Therapy for Patients with Severe Infections: Choosing the Right Drug at the Right Dose. Antibiotics for Clinicians 2004;(8)July-September:265-270. 267. Sun HK, Maglio D, Nicolau DP. Macrolide Resistance in Streptococcus Pneumoniae: Mechanisms and Patterns Resistance. Connecticut Medicine 2004;68(9):571-576. 268. Maglio D, Nicolau DP. Antibiotic Efficacy Review. Infectious Disease Special Edition 2004. McMahon Publishing Group 2004;7:33-36. Cystic Applying Pharmacodynamic Concepts to Meropenem Therapy. of of Chromatography B 2004;811:225-229. 271. Nicolau DP. Treatment with Appropriate Antibiotic Therapy in Community Acquired Respiratory Tract Infections. American Journal of Managed Care Suppl 2004;10(12) Suppl:S381-S388. 272. Nicolau DP. Management of Respiratory Tract Infections: A Focus on Appropriate Antibiotic Utilization. American Journal of Managed Care Intravenous to Oral Conversion Programs for Anti-Infectives in the United States. Hospital Pharmacy 2004;39(11):1069-1075. 274. Zhang C, Nightingale CH, Nicolau DP. Reverse Phase High Performance Liquid Chromatographic Method for Determination of Moxifloxacin in special growth media. Chinese Pharmaceutical Journal 2004; 39(9):699-701. 275. Nicolau DP. Choosing the Right Therapy for CARTIs. Journal of Respiratory Diseases 2004; 25(12 Suppl):S7-8. Dr. David Nicolau's Scholarship 11/7/11 31 Antibiotics Used to Treat Community-Acquired Respiratory Infections: Key Determinants of Patient Outcomes and Risk for Resistance Development. Journal of Respiratory Diseases 2004; 25(12 Suppl):S27-34. 277. Zhang C, Nightingale CH, Nicolau DP. Development and Optimization of a Reversed Phase High Performance Liquid Chromatographic Method for the Determination of Levofloxacin in Growth Media, Human BAL Fluid, Alveolar Macrophage and Plasma. Journal of Infectious Diseases Pharmacotherapy 2004;6(4):49-57. 278. Maglio D, Nicolau DP. The Integration of Pharmacokinetics and Pathogen Susceptibility in the Design of Rational Dosing Regimens. Methods and Findings in Experimental and Clinical in a Neutropenic Infection Antimicrobial Agents & Chemotherapy 2005;49(1):188-194. 280. Maglio D, C, Klebsiella pneumoniae and Escherichia coli in a Murine Model. Antimicrobial Agents & 2005;49(1):276-280. 281. Fetterly Ong Nicolau DP. Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid Following a 200-mg Dose for Three Days or a Single 800-mg Dose. Antimicrobial Agents & Chemotherapy PG, Predict Critical Pharmacodynamic Target Attainment Against Common Nosocomial Pathogens in Europe, 2002: OPTAMA Fungal Infections. Formulary 2005;40(1):13-21. Dr. David Nicolau's Scholarship 11/7/11 32 Xuan D, Ye M, Nicolau DP, Nightingale CH. Simultaneous Piperacillin In Owens RC Jr., Nightingale CH, Ambrose PG, eds. Antibiotic Optimization: Concepts and Strategies in Clinical Practice. New York, NY: Marcel Dekker and Economic Advantages of Continuous Infusion of -Lactam Antibiotics. Intensive and Critical Nursing 2005;21:87-93. 287. Sun HK, Ong CT, Umer A, Harper D, S, Pharmacokinetic Profile of Tigecycline Blister Fluid After Multiple Intravenous Administrations. Antimicrobial Agents & Chemotherapy 2005;49(4):1629-1632. DP. When \"S\" Doesn't Mean Success: The Importance of Choice of Antibiotic and Dose on Clinical and Economic Outcomes of Severe Infection. Connecticut Medicine 2005;69(4):203-210. 289. Owens RC, Jr., McKinnon PS, Nicolau DP. Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus. Informed Decisions: Clinical Strategies for JL, Connecticut Medicine 2005;69(5):271-275. 291. Dandekar Farrell DJ, CH, Nicolau DP. Assessment of the Efficacy of Telithromycin Simulating Human Exposures Against S. Pneumoniae With Ribosomal Mutations in a Murine Pneumonia Model. International Journal of Antimicrobial Agents 2005;25:530-534. 292. DeRyke CA, Maglio D, Nicolau DP. Defining the need for new antimicrobials: Clinical and economic implications of resistance in the hospitalized patient. Expert Opinion on Pharmacotherapy 2005;6(6):873-889. Dr. David Nicolau's Pharmacodynamic Target Attainment Between Subject and Patient Data -Lactams. 2005;25(7):935-941. 294. Kuti JL, Nicolau Veno-Venous Hemofiltration Based Kuti JL. Optimizing Antibiotic-Related Outcomes in the Critically Ill Patient. Infectious Diseases in Clinical Practice 2005;13(4):158-164. 296. Li C, Kuti JL, and Pharmacodynamics of Piperacillin/Tazobactam in Patients Intra-abdominal Nosocomial Bloodstream Infections: A Report from the OPTAMA Program. Clinical Therapeutics 2005;27(7):1032-1042. 298. Du X, Li C, Sun H, Nightingale CH, Nicolau DP. A and Broncho-alveolar Lavage Fluid by Liquid-liquid Extraction and Reversed Phase HPLC. Journal of Pharmaceutical and Biomedical Analysis 2005;39:648-652. 299. Sun HK, Lee SY, Banevicius MA, Du X, Pulsatile Amoxicillin and Alone and in Combination in a Murine Pneumococcal Pneumonia Model. Journal of Telithromycin against S. Pneumoniae With Ribosomal Mutations utilizing in vitro Time Kill Methodology. International Journal of Antimicrobial Agents 2005;26:331-334. Dr. David Nicolau's Scholarship 11/7/11 34 Resistance among Gram-Positive Pathogens: Review of Epidemiological Characteristics and Treatment Options for Methicillin-Resistant Staphylococcus aureus (MRSA). Pharmacy Practice News 2005;9:39-44. 303. Nosocomial Pneumonia: A Report from the OPTAMA Program. Critical producing Klebsiella Species and Escherichia coli on DP. Pharmacodynamics of Antimicrobials: Treatment Optimization. Expert Opinion on Drug Metabolism and Toxicology 2005;1(3):351-361. 307. Lee SY, Kuti JL, Nicolau DP. Antimicrobial Management of Complicated Skin and Skin Structure Infections in the Era of Emerging Resistance. Surgical Infections 2005;6(3):283-295. 308. Kotapati S, Kuti JL, for the Empiric Treatment of Secondary Peritonitis: A report from the OPTAMA Program. Surgical Infections 2005;6(3):297-304. 309. Brook I, Giraldo DE, A, Nicolau ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without 60Co gamma-irradiation. Journal of Medical Microbiology 2005;54:1157-1162. 310. Farr GE, Nicolau DP. Respiratory Tract Infections: Focus on Efficacy and Safety of Current Treatment Options. Advanced Studies in Pharmacy 2005;2(6):210-211. Dr. David Nicolau's Scholarship 11/7/11 35 311. Study: A 64-year-old Man with \"Collateral Damage\". Advanced Studies in Pharmacy. Advanced Studies in Pharmacy 2005;2(6):241-244. 312. Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. Pharmacokinetics of Clarithromycin Extended-Release (ER) Formulation in Patients with AIDS. HIV Clinical Trials 2005;6(5):246-253. 313. Kuti JL, Nicolau DP. Making the Most of Surveillance Studies: Summary of the OPTAMA Program. Diagnostic Microbiology and 2005;53:281-287. 314. Ellis JM, Kuti JL, Nicolau DP. Use Assess the Pharmacodynamics of Beta-lactams against Pseudomonas aeruginosa Infections in Children: A from the OPTAMA Therapeutics Peloquin C, GD, eds. Antimicrobial Therapy and Vaccines. Volume Antimicrobial Agents. Second Edition. Pittsburgh, PA: ESun Technologies, 2005:21-44. X, DP. Population Pharmacokinetics and SY, Kuti JL, Nicolau DP. for a Development of Resistance. Drugs 2006;66(1):1-14. 319. Sun HK, Duchin K, Nightingale CH, Shaw JP, J, Nicolau DP. Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects. Antimicrobial Agents & 2006;50(2):788-790. 320. Ong Therapy of Skin Dr. David Nicolau's Scholarship 11/7/11 36 and Soft Tissue Infections: A Report from the OPTAMA Program. Surgical Infections 2005;6(4):419-426. 321. Gerbino PP, Brixner D, Sbarbaro J, Nicolau D. Appropriate Initial Antibiotic Therapy in the Treatment of Community-Acquired Respiratory Tract Infections. Managed Care Interface 2005;18(12):41-48. 322. Sbarbaro J, Nicolau DP, Asche C. Management of Community-Acquired Respiratory Tract Infections in an Era of Increasing Antibiotic Resistance. Pharmacy and Therapeutics 2006;31(2):106-111. 323. DeRyke CA, Kuti JL, Mansfield D, Dana Nicolau DP. Pharmacoeconomics of Continuous versus Intermittent Infusion Piperacillin/tazobactam for the Treatment of Hospitalized Patients with Complicated Intra-abdominal Infection. American Journal of Health-System for Pediatric Meningitis - A Report from the OPTAMA Program. Pediatric Drugs 325. of the Microemulsion Formulation of Cyclosporin A (Neoral) In Renal Transplant Patients. Therapy 2006;3(2):259-264. 327. Kuti JL, Ong C, Lo M, Melnick N, Nicolau DP. Comparison of Pharmacodynamic Target Attainment Calculated by Monte Carlo Simulation with Microbiological Response for Two Carbapenems in the Treatment of Complicated Skin and Skin Structure Infections. International Journal of Antimicrobial Agents 2006;28:62-68. 328. Lee on Antibiotic. Expert Opinion on Pharmacotherapy 2006;7(10):1381-1397. 329. DeRyke CA, Du X, Nicolau DP. Evaluation of Bacterial Kill when Modeling the Bronchopulmonary Pharmacokinetic Profile of Moxifloxacin and Levofloxacin Dr. David Nicolau's Scholarship 11/7/11 37 against parC Containing Isolates of S. pneumoniae. Journal of Antimicrobial Chemotherapy 2006;58:601-609. 330. Sun HK, Nicolau DP, Kuti JL. Resource Utilization of Adults Admitted to a Large Urban Hospital with Community-Acquired Pneumonia caused by Streptococcus pneumoniae. Regimen Optimization of Meropenem in Adult Journal Beta-lactamase producing Escherichia coli and Klebsiella spp from the MYSTIC Program in Brazil. International Journal of Antimicrobial Agents 2006;28:340-344. 333. Kioumis IP, Nicolau DP. Antimicrobial Efficacy Review. Pharmacy Practice News. 2006;33(9) :29-32 ; Infectious Disease Special Edition. 2006;67-70. McMahon Lee SY, against Pathogens Implicated in the Cause of Complicated Skin and Soft Tissue Infections: A Report from the OPTAMA Program. Infectious Diseases in Clinical Practice 2006;14:289-295. 335. Scheetz Reddy coli and Klebsiella spp. Containing Extended Spectrum -lactamases. American Journal of Infectious Diseases 2005;1(3):149-155. 337. Lau W, Mercer D, Itani K, Nicolau D, Kuti J, Mansfield D, Dana A. A Randomized, Open-Label, Comparative Study of Piperacillin/Tazobactam Administered by Continuous Infusion vs. Intermittent Infusion for the Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection. Antimicrobial Agents & Chemotherapy 2006;50(11):3556-3561. Dr. David Nicolau's Scholarship 11/7/11 38 338. DeRyke without Co-Administration of Gentamicin Against Isolates of Staphylococcus aureus and Enterococcus species. Antimicrobial Agents & Chemotherapy Attainment Against Pseudomonas aeruginosa Collected in Hungarian Hospitals. International Journal of Antimicrobial Klebsiella Species on Hospital Costs: A Matched Cohort Study. Infection Control and Hospital Epidemiology 2006;27(11):1226-1232. 341. Kim SW, Kuti JL, Nicolau SY, Novel Rifamycin, a Murine Pneumococcal Pneumonia Model. Journal of Antibiotics 2006;59(12):804-807. 343. Sun HK, Du X, DeRyke CA, Doern GV, DP. ParE Mutations May Bactericidal Activity of Respiratory Fluoroquinolones. International a 2-year period: Results of the 2004 OPTAMA Program in North America. Infectious Diseases in Clinical Practice 345. Kioumis IP, Kuti JL, Nicolau Expert Opinion on Pharmacotherapy 2007;8(2):167-182. 346. Pseudomonas aeruginosa MexA-MexB-OprM Efflux Diagnostic Microbiology and Infectious Disease 2007;57:153-161. Dr. David Nicolau's Scholarship 11/7/11 39 347. DeRyke CA, Nicolau DP. Is All Free Time Above the Minimum Inhibitory Concentration the Same: Implications for -lactam In vivo Modeling. International Journal baumannii, Escherichia coli, and Klebsiella Species Collected from United States Intensive care Units in 2004. Pharmacotherapy 2007;27(3):333-342. 349. Lee SY, Fan HW, DP. Antibacterial Effects of Moxifloxacin and Levofloxacin Simulating Epithelial Lining Fluid Concentrations against Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA). Drugs in Research Laohavaleeson JL, New Lipoglycopeptide for Resistant Gram-Positive Infections. Expert Opinion on Investigational 351. Nicasio Oral Antibiotics: If the Gut Works Use It? Antibiotics for Clinicians 2007;Jan-March: 396-401. 352. DeRyke CA, Fan Extended-Spectrum coli Pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrobial Agents & Chemotherapy 2007;51(4):1481-1486. 353. Nicolau DP, Sutherland A, Dagan R, Pichichero ME. Pharmacokinetics of Cefprozil in Plasma and Middle Ear Fluid of Children Undergoing Treatment for Acute Otitis Media. Pediatric Drugs (ESBL) and Non-ESBL Infections. Journal of Infection 2007;54:463-468. Dr. David Nicolau's Scholarship Clinical Pharmacodynamics of with Lower Respiratory Tract Infections and Intra-abdominal Infections. Antimicrobial Agents & Pharmacodynamic Modeling: Application to Meropenem Dosage and Combination Therapy. Clinical Microbiology & Infection 2007;13:579-585. 357. DeRyke CA, Kuti JL, Nicolau DP. Cumulative Fraction of Response as a Surrogate Marker for Antibiotic Efficacy in Incremental Therapy in Acute Exacerbations of Chronic Bronchitis Previously Treated with Azithromycin. Journal Dalbavancin, the Carlo Simulation Model to Optimize the Initial Empiric Antimicrobial Therapy for Gram-Negative Bacterial Infections in an Adult Intensive Care Unit of a Tertiary Care Hospital in Brazil. Brazilian Journal of Infectious Disease 2007;11(2):183-185. 362. Santos FL, Kuti JL, Pharmacodynamic Principles to Optimize Antimicrobial Treatment in the Face of Emerging Resistance. Brazilian Journal of Microbiology 2007;38:183-193. 363. Sutherland C, Nicolau DP. Development of an HPLC Method for the Determination of Doripenem in Human and Mouse Serum. Journal of Chromatography B for Gram-Negative Rods Based on Pharmacodynamic Assessment. Diagnostic Microbiology and Infectious Disease 2007;58:337-344. 367. Nicasio Quintiliani R of 368. Nicolau DP. Optimizing the Use of Carbapenems in the Face of Increasing Gram-Negative Resistance. Supplement Editor. Formulary 2007; July Supplement:1-15. M, Dowell JA. Pharmacokinetics of Dalbavancin in Plasma and Skin Blister Fluid. Journal of Antimicrobial Chemotherapy 2007;60:681-684. 370. Sahni JK, Kuti JL, Nicolau DP. A Time Motion Study to Determine Differences in Pharmacy Technician Workload Attributed to Preparation of a Novel Reformulation of Piperacillin/Tazobactam (Zosyn\u00ae) with its Original Formulation. Pharmacy Technology 2007;23:203-206. 371. Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP. Pharmacodynamic Target Attainment of Seven Antimicrobials against Gram-negative Bacteria collected from China in 2003 and 2004. International Journal of Antimicrobial Agents 2007;30:452-457. 372. Newman D, Scheetz Dr. David Nicolau's Scholarship GV, Gallagher G, Abramson MA. A Pharmacodynamic Analysis of Resistance Trends in Pathogens from Patients with Infection in Intensive Care Units in the United States between 1993 and 2004. Annals of Clinical Microbiology and Antimicrobials 2007;6(11):1-6. 375. Nicolau DP. Carbapenems: A Potent Class against Clinical Isolates of Staphylococcus aureus and Coagulase-negative Staphylococci Collected from Hospitals in Brazil. Clinical Microbiology & Infection 2008:14:116-123. 377. Nicasio AM, Kuti JL, Resistant Gram-negative Bacilli in North America: Insights from the Society of Infectious Diseases Pharmacists. 378. Review on Inhaled Antimicrobial Therapies for Respiratory Infections. Current Infectious Disease Reports 2008;10:29-36. 381. Kuti JL, Dowzicky Common Intravenous Antibiotics for the Empiric Treatment of Complicated Skin and Soft Tissue Infections. Surgical Infections 2008;9(1):57-66. 382. Kuti JL, Dowzicky M, Nicolau DP. to Assess Tigecycline Predicted Efficacy for Hospital-Acquired Pneumonia. Journal of Chemotherapy 2008;20(1): 69-76. Dr. David Nicolau's Scholarship 11/7/11 43 383. Bugs vs. Drugs: What is the Battle against Serious Gram-Positive Pathogens. Future Microbiology 2008;3:251-263. 385. Kim A, Profiling Pseudomonas by Simulating Human Exposures. Antimicrobial Agents 386. Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Model Caused by Phenotypically Diverse Staphylococcus aureus. Antimicrobial Agents & Chemotherapy 2008;52(7):2389-2394. 387. Nicolau DP. Pharmacodynamic Optimization of Beta-lactams in Care 2008;12(Suppl Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of Automated Screening and Confirmation of Extended Spectrum -Lactamase Producing Enterobacteriaceae on Antibiotic Prescribing. Journal of for the Empiric Treatment of Acute Otitis Media in Children. Pediatric Drugs 2008;10(5):329-335. 390. Nicolau DP. Pharmacokinetic and Nicolau DP. Urinary Activity of Single Doses (250, 500, 750, 1000 milligrams) of Levofloxacin against Fluoroquinolone-resistant Strains of Escherichia coli. International Agents 2008;32:320-325. 392. Beneri CA, Nicolau DP, Seiden HS, Rubin LG. Treatment of a Neonate with Persistent Vancomycin-Resistant Enterococcal Bacteremia with a Daptomycin-Containing Regimen. Infection and Drug Resistance 2008;1:9-11. Dr. David Nicolau's Scholarship 11/7/11 44 393. Charifson PS, Grillot AL, Grossman Parsons JD, Badia S, Deininger DD, Drumm Ronkin S, Swenson LL, Tang Q, Tesier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D. Novel Dual Targeting Aminobenzimidazole Urea Inhibitors of DNA Gyrase & Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution Through the Judicious Use of Structure and SAR. Journal of Medicinal Chemistry 2008;51(17):5243-5263. 394. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP. Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers by In Vivo Microdialysis. Antimicrobial Agents Oral Beta-lactam Regimens against Hemophilus influenzae in Children. Pediatric aeruginosa with Discordant Cefepime / Ceftazidime Susceptibility Profiles. Infection and Drug Resistance of Telavancin versus Vancomycin for the Treatment of Complicated Skin and Skin Structure Principles: the Case for Prolonged Infusion Beta-Lactam Antibiotic Therapy. Brazilian Journal of Infectious Diseases 2008;12(Suppl. Kioumis Orthopedic Trauma Patient. In Browner BB, Jupiter JB, Levine AM, Trafton PG, Krettek C, eds. Skeletal Trauma: Basic Science, Management, and Reconstruction, Volume I: General Principles, Spine, Pelvis. 4th ed, Philadelphia, PA: Saunders 2009:258-264. 400. Dandache P, Nicolau pneumoniae Meningitis. Infectious Diseases in Clinical Practice David Nicolau's Scholarship 11/7/11 45 401. E, Nicolau DP. Tackling Empiric Antibiotic Therapy for Ventilator-Associated Pneumonia in Your ICU: Guidelines for Implementing the Guidelines. Seminars in Respiratory and Critical Care Medicine 2009;30:102-115. on Hospital Length of Stay and Costs in Patients with Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine 2009;30:116-124. 403. Nicolau DP. Containing Costs and Containing Bugs: Are They Mutually Exclusive? Journal of Managed Care Pharmacy 404. Nicasio of Micafungin in Healthy Staphylococcus Aureus in a Murine Thigh Model. Antimicrobial Agents & Chemotherapy 2009;53(3):1165-1169. 406. Nicolau DP. Spotlight on Clostridium difficile Infection: An JL, Programs for the US Hospitals: Focus on Gram-Negative Comparison of the Cumulative of Response for 19 Antibiotic Regimens against Nosocomial Pathogens in Europe between 2002 and 2006. International Journal of Antimicrobial Agents 2009;33(4):348-353. 409. Kim A, Sakoulas G, DP. Prevalence of Methicillin-Resistant Staphylococcus aureus (MRSA) Strains with Vancomycin MIC 2 \u00b5g/mL in New York City Area Hospitals and Implications on Pharmacodynamic Target Attainment. Infectious Diseases in Clinical Practice 2009;7(2):95-98. 410. Nicasio AM, in Dr. David Nicolau's Scholarship 11/7/11 46 Adult Critically-Ill Patients with Ventilator Associated Pneumonia. Antimicrobial Agents & Chemotherapy 2009;53(4):1476-1481. 411. Koomanachai P, Kim DP. Tigecycline against Acinetobacter Baumannii Model. Journal of Antimicrobial Chemotherapy 2009;63(5):982-987. 412. Nicolau DP. Management of Complicated Infections in the Era of Antimicrobial Resistance: The Role of Vancomycin Minimum Inhibitory Concentrations among Methicillin-Resistant Staphylococcus aureus Isolated from Patients with Ventilator Associated Pneumonia at a Connecticut Hospital. Connecticut Medicine 2009;73(6):337-340. 414. Nicolau DP. What is the 360-Degree Approach to Defining Success for VAP? Journal of Managed Care Pharmacy 2009;15(Suppl)5:S3-S4. 415. Nicolau DP. Infection with Meropenem High-Level Resistant Pseudomonas aeruginosa. Infection Control and Hospital Kuti JL, Girotto JE, bactericidal exposure for -lactams via extended infusions in the pediatric population. Pediatric Blood & Cancer 2009;53:379-385. 419. Rodvold KA, Nicolau Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL. Identifying Exposure Targets for the Treatment of Staphylococcal Pneumonia with Ceftobiprole. Antimicrobial Agents & Chemotherapy 2009;53(8):3294-3301. Optimal Diagnosis and Treatment. Continuing Medical Education Supplement, Advancing Knowledge in Healthcare, Inc., 2009;1-8. 422. Eagye KJ, Nicolau DP. Incidence of Infection and Impact on Hospital Length of Stay and Costs in Patients Undergoing Elective Colorectal Surgery. American Journal of Surgery 2009;198:359-367. 423. DP. Site Infections: Does Inadequate Antibiotic Affect Patient Outcomes? Surgical Infections 2009;10(4):323-331. 424. Crandon JL, Kim A, Nicolau DP. Comparison of Tigecycline Penetration into the Epithelial Lining Fluid of Infected and Uninfected Murine Lungs. Journal of Prolonged Infusions of Doripenem against Pharmacy Practice News. 2009;(9):29-32 ; Infectious Disease Special Edition. 2009. McMahon Publishing Group, New York, NY. 427. Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society Criteria to Predict Severe Community Acquired Pneumonia Caused by Streptococcus pneumoniae. American Journal of Emergency Medicine 2009;27:968-974. 428. JL, Profile of Tigecycline against Methicillin-Resistant Staphylococcus aureus in an Experimental Pneumonia Model. Antimicrobial Agents & Chemotherapy 2009;53(12):5060-5063. 429. of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrobial Agents & Chemotherapy 2009;53(12):5102-5107. 430. Koomanachai P, Crandon JL, Nicolau DP. Newer Developments in the Opinion on Pharmacotherapy in Cystic Fibrosis - A Review of 3 Cases. Respiratory Medicine CME 2009, doi:10.1016/j.rmedc.2009.09.011 432. Bulik CC, Christensen H, aeruginosa Displaying Various Resistance Phenotypes, Including Multi-drug Resistance. Antimicrobial and Ventilator-Associated Pneumonia: Update from the of Escherichia coli and Pseudomonas aeruginosa at 40 U.S. Hospitals. Clinical Therapeutics 2009;31(11):2678-2688. 435. Nicolau DP, Stein GE. Therapeutic Options for Diabetic Foot Infections: A Review with an Emphasis on Tissue Penetration Characteristics. Journal of the American Podiatric Medical Association 2010;100(1):52-63. 436. Bulik DP, Kuti JL. Comparison of the Activity of a Human Simulated, High Dose, Prolonged Infusion of Meropenem against Klebsiella pneumoniae Producing the KPC Carbapenemase versus that Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model. Antimicrobial 2010;54(2):804-810. A Pharmacodynamic-Based Clinical Pathway for Empiric Antibiotic Choice in Dr. David Nicolau's Scholarship 11/7/11 49 Patients Infected with Ventilator-Associated Pneumonia. Journal Patients with Reduced Renal Function: An Update to Our Clinical Pathway. Journal of Critical Pseudomonas aeruginosa. Antimicrobial Agents & Chemotherapy 2010;54(3):1111-1116. 440. Ray L, Levasseur K, Nicolau DP, Scheetz MH. Cerebral Spinal Fluid Concentrations of Tigecycline in a Patient with Acinetobacter Absence of Use of Ertapenem and Change in Antipseudomonal Carbapenem Susceptibility Rates in 25 Hospitals. Infection Control and against Gram-Negative Bacteria Collected in the United States Today (TRUST) 12 Surveillance Program. Clinical Therapeutics 2010;32(4):766-779. JL. of Stay and Hospital Costs Associated with a Pharmacodynamic-Based Clinical Pathway for Empiric Antibiotic Choice in Patients with Ventilator-Associated Pneumonia. Pharmacotherapy 2010;30(5):453-462. Carbapenemase-Producing Klebsiella pneumoniae Isolates by Various Testing Methods. Journal of Clinical Microbiology 2010;48(7):2402-2406. 445. Crandon JL, Sutherland CA, Nicolau DP. Extended Room Temperature Stability and Long-Term Storage Options for Doripenem within Two Infusion Containers. American Journal Health-System Pharmacy 2010;67:1539-1544. Dr. David Nicolau's CC, Nicolau DP. In Efficacy Doripenem against Carbapenemase Klebsiella GH, Nicolau DP. Overview Perspective of Bacterial Resistance. Expert Opinion on Therapeutic Patents 2010;20(10):1273-1276. 448. Keel RA, Sutherland CA, Aslanzadeh J, Nicolau DP, Kuti JL. Correlation between Vancomycin and Daptomycin MIC Values for Methicillin-Susceptible and -Resistant Staphylococcus aureus by Three Testing Methodologies. Diagnostic Microbiology and Diseases Exposures of Telavancin and Vancomycin against Methicillin Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model. Antimicrobial Agents & Chemotherapy 2010;54(12):5115-5119. 450. Tissue Penetration and Pharmacokinetics of Tigecycline in Diabetic Patients with Chronic Wound Infections Described by Using In Vivo Microdialysis. Practice News Special Edition. 2010:61-67. McMahon Publishing Group, New York, NY 452. Bulik in Cystic Fibrosis - A Review of 3 Cases. Respiratory Medicine CME 2010;3:146-149. 453. Crandon J, Nicolau DP. Oritavancin (Chapter 48). In Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. Kucers' Use of Antibiotics, 6th ed, London, In Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. Kucers' Use of Antibiotics, 6th ed, London, UK: Hodder Arnold 2010;645-653. Dr. David JL, 50). In Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. Kucers' Use of Antibiotics, 6th In Kumar A, ed., Optimizing Antimicrobial Therapy of Sepsis and Septic Shock, Critical Care Clinics 2011;27:77-93. 457. Stein GE, Smith C, Kim G, Dybas L, Chung W, Nicolau DP. Serum Bactericidal of Streptococcus pneumoniae with First-step Mutations. Infectious Diseases in Clinical Practice 2011;19:29-33. 458. Keel RA, Sutherland CA, Crandon JL, Nicolau DP. Stability of Doripenem, imipenem and Meropenem Elevated Room Temperatures. International Journal of Antimicrobial Agents 2011;37:184-185. 459. Nicolau DP. Current Challenges in the Management of the Infected Patient. Current Opinion in Infectious Diseases 2011;24(Suppl 1):S1-S10. 460. Koomanachai P, DP, Kuti JL. Linezolid Penetration into Wound Tissue of Two Diabetic Patients Before and After Hyperbaric Oxygen Therapy. Undersea & Hyperbaric Medicine 2011;38(1):11-16. 461. against Prevalent Gram-negative Organisms across the Globe: The PASSPORT Program - Asia-Pacific Region. International Journal of Antimicrobial Agents 2011;37:225-229. Optimization of Meropenem Dosage in the Critically Ill Population Based on Renal Function. Intensive Care Medicine 2011;37:632-638. 463. Vitro Pharmacodynamics of Pulmonary Exposures of Tigecycline Alone and in Combination with Meropenem or Rifampin against Klebsiella Producing the DP. Fluoroquinolone Use Is Not with the Change in Imipenem Susceptibility of Pseudomonas aeruginosa in 25 Hospitals. Advances 2011;28(4):326-333. DP, Kuti JL. Development of an HPLC Method for the Determination of Anidulafungin in Human Plasma and Saline. Carbapenem Susceptibility in 25 Hospitals over 9 Years Is Not Associated with the Use of Ertapenem. Journal of Antimicrobial Chemotherapy 2011;66:1392-1395. 469. Vivo of a Human-Simulated Regimen with NXL104 against ESBL and Non-ESBL-Producing Enterobacteriaceae. Antimicrobial & Chemotherapy Nicolau DP. The Use of Scoring Systems to Predict Prognosis in Patients with Ventilator Associated Pneumonia. Clinical Pulmonary Medicine 2011;18(4):181-185. Dr. David Nicolau's Scholarship 11/7/11 53 ABSTRACTS 1a. Nicolau DP, Mu-Chow K, Dobson D. The effect of the clinical pharmacist on the prescribing of amikacin. Eastern States Residents Conference, April 1988 2a. Nicolau DP, Mu-Chow K, Dobson D. The effect of the clinical pharmacist on the prescribing of amikacin. New England Council of Hospital Pharmacists, 35th Annual Spring Seminar, May 1988 3a. Nicolau DP, Mu-Chow K, Dobson D. The effect of the clinical pharmacist on the prescribing of amikacin (Abstract No. P-379E). American Society of Hospital Pharmacists, 23rd Annual Midyear Clinical Meeting, December 1988 4a. Nicolau DP, White RL, Friedrich LV, Kays MB. The impact of the antibiotic order form on antibiotic use in the burn treatment center (Abstract No. P-345R). American Society of Hospital Pharmacists, 24th Annual Midyear Clinical Meeting, December 1989 5a. Nicolau DP, Strange C, Dryzer SR. Chylous transport of amiodarone. American College of Clinical Pharmacy, 1991 Winter Practice & Research Forum, February 1991 6a. Nicolau DP, Strange C, Dryzer SR. Chylous transport of amiodarone. Twenty-Second Annual Southeastern Conference for Postgraduate Pharmacy Education and Training, April 1991 7a. Nicolau DP, Hogan KR. National survey of mesna use for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplant patients (Abstract No. P-462D). American Society of Hospital Pharmacists, 26th Annual Midyear Clinical Meeting, December 1991 8a. Nicolau DP, Uber WE, Crumbley AJ, Strange C. Amiodarone-cyclosporine interaction in a cardiac transplant patient (Abstract No. 31). American College of Clinical Pharmacy, 1992 Winter Practice & Research Forum, February 1992 9a. Nicolau DP, Freeman CD, Maderazo EG, Cooper BW. Influence of aspirin on the development of experimental endocarditis due to Staphylococcus aureus (Abstract No. B250). American Society for Microbiology, 92nd General Meeting, May 1992 Dr. David Nicolau's Scholarship dosing methods and monitoring nomogram (Abstract No. 208). American Society for Microbiology, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) implementation of a once-daily aminoglycoside program (Abstract No. P-462D). American Society of Hospital Pharmacists, 27th Annual Midyear Clinical Meeting, December 1992 12a. Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani Minocycline versus vancomycin for the treatment of experimental oxacillin-resistant Staphylococcus aureus endocarditis (Abstract No. A103). American Society for Microbiology, 93rd General Meeting, Atlanta, Georgia, May 1993 13a. Nicolau DP, Ross JW, Nightingale effects of pneumocystis carinii pneumonia therapy (Abstract No. PO-D28-4232). IX International Conference on AIDS, Berlin, Germany, June 1993 Freeman noninflammatory extracellular blister fluid; inflammatory and noninflammatory white blood cells and paper disk (Abstract No. 726). American Society for Microbiology, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 1993 of ceftizoxime plus metronidazole compared with cefoxitin and ampicillin/sulbactam (Abstract No. 419). American Society for Microbiology, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 1993 Experience with 500 patients in a hospital-wide program (Abstract No. 85). American Society for Microbiology, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 1993 Dr. David Nicolau's Scholarship of time above the minimum inhibitory concentration (Abstract No. 87). American Society for Microbiology, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 1993 18a. Hitt CM, Patel KB, on once-daily gentamicin pharmacokinetics. Thirteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors, Baltimore, Maryland, April 1994 19a. Nicolau DP, Marangos M, Nightingale CH, Quintiliani R. Influence of aspirin dosage on the development of experimental S. aureus endocarditis (Abstract No. B239). American Society for Microbiology, 94th General Meeting, Las Vegas, Nevada, May 1994 20a. Nicolau DP, Marangos M, Nightingale CH, Quintiliani R. Influence of aspirin on the treatment of experimental S. aureus endocarditis (Abstract No. A6). American Society for Microbiology, 94th General Meeting, Las Vegas, Nevada, May 1994 complex in human macrophages (Abstract No. A43). American Society for Microbiology, 94th General Meeting, Las Vegas, 118 patients with postpartum endometriosis (Abstract No. 114). American College of Clinical Pharmacy, Annual Meeting, St. Louis, Missouri, July-August 1994 23a. Nicolau Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients (Abstract No. 115). American College of Clinical Pharmacy, Annual Meeting, St. Louis, Missouri, the treatment of experimental Enterococcus faecalis endocarditis (Abstract No. 7). Connecticut Infectious Diseases Society, 10th Annual Meeting, Southbury, Connecticut, September 1994 Dr. David Nicolau's Scholarship febrile and afebrile patients (Abstract No. 8). Connecticut Infectious Diseases Society, 10th Annual Meeting, Southbury, Connecticut, September 1994 with streptomycin against VanB-type resistant enterococci with variable levels of Vm-resistance (Abstract No. 2). Connecticut Infectious Diseases Society, 10th Annual Meeting, Southbury, Connecticut, R. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental VanB-type resistant enterococcal endocarditis (Abstract No. 1). Connecticut Infectious Diseases Society, 10th Annual Meeting, Southbury, Connecticut, September 1994 28a. Nicolau Quintiliani R. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple-dose caffeine (Abstract No. 57). 5th International Symposium on New Quinolones, Singapore, August in rabbits (Abstract No. P45). American Association for Laboratory Animal Science, 45th Annual Meeting, Pittsburgh, Pennsylvania, October 1994 MN, Nicolau combined with streptomycin (Sm) against VanB-type resistant enterococci with variable levels of Vm-resistance (Abstract No. E100). American Society for Microbiology, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October Belliveau and afebrile patients (Abstract No. A39). American Society for Microbiology, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 32a. Nightingale 57 intracellulare (Abstract No. E138). American Society for Microbiology, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, R. Efficacy of vancomycin (Vm) and teicoplanin (Te) alone and in combination with streptomycin (Sm) in experimental enterococcal endocarditis (Abstract No. B73). American Society for Microbiology, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 1994 34a. Nicolau activity: Continuous infusion versus intermittent injections (Abstract No. A90). American Society for Microbiology, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Belliveau PP, Nicolau in the hospital setting/cost containment by switching from parenteral to oral therapy (Abstract No. Is-100). 4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Manila, Philippines, December 1994 36a. Hitt CM, Patel KB, (Abstract No. P-437E). American Society of Hospital Pharmacists, 29th Annual Midyear Clinical Meeting, Miami, Florida, December 1994 37a. Klepser ME, Patel KB, Nicolau DP, with and piperacillin against Pseudomonas aeruginosa. The Role of Quinolones in Hospital Pharmacy, Poster symposium presented during American Society of Hospital Pharmacists, 29th Annual Midyear Clinical Meeting, Miami, Florida, December 1994 38a. Nicolau DP, Ross JW, Nightingale CH, Quintiliani R. Influence gender on treatment outcomes and pharmacoeconomics of Pneumocystis carinii pneumonia (PCP) in patients with AIDS (Abstract No. 299). Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., January-February 1995 Dr. the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine (Abstract No. 68). American College of Clinical Pharmacy, Winter Practice and Research Forum, Orlando, Florida, February 1995 40a. Nicolau intermittent dosing combined with once-daily gentamicin or ciprofloxacin (Abstract No. 42). American College of Clinical Pharmacy, Winter Practice and Research Forum, Orlando, Florida, February 1995 41a. Marangos MN, Skoutelis CH. Absorption of ciprofloxacin in patients with diabetic gastroenteropathy (Abstract No. 416). 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, March 1995 42a. Xuan D, Nicolau DP, R, Endotoxin concentration reduction with the addition of 5S-IgG immunoglobulin in the presence of cefotaxime (Abstract No. 1290). 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, March 1995 43a. Banevicius MA, Epp E, Nightingale CH, Nicolau DP. Influence Oxyrase on the microdilution susceptibility testing of B. fragilis to five antimicrobials (Abstract No. C362). American Society for Microbiology, 95th General Meeting, Washington, D.C., May 1995 44a. Klepser ME, Patel KB, Nicolau DP, with ceftazidime and piperacillin against Pseudomonas (Abstract No. 3053). 19th International Congress of Chemotherapy, Montreal, Marangos MN, Nicolau DP, Nightingale CH, Quintiliani the treatment of experimental Enterococcus faecalis and methicillin-resistant Staphylococcus aureus endocarditis (Abstract No. 3054). 19th International Congress of Chemotherapy, Montreal, Canada, July 1995 46a. Nicolau DP, Nightingale R. Effect of fleroxacin and ciprofloxacin on the pharmacokinetics of Dr. David Nicolau's Scholarship 11/7/11 59 caffeine (Abstract No. 3273). 19th International Congress of Chemotherapy, Montreal, Canada, July 1995 Nightingale CH, Nicolau DP, on the Pharmacodynamics of Antimicrobials, Presented during the 19th International Congress of Chemotherapy, Montreal, Canada, July 1995 48a. Klepser ME, Zhu Z, Nicolau absorption for trimethoprim/ sulfamethoxazole (160mg/800mg) in patients with AIDS (Abstract No. 115). American College of Clinical Pharmacy, Annual Meeting, Washington, D.C., August 1995 49a. Patel KB, Nicolau DP, intermediate penicillin-resistant Streptococcus pneumoniae (Abstract No. A87). American Society for Microbiology, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 1995 50a. aminoglycoside program (Abstract No. N18). American Society for Microbiology, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 1995 51a. Alkhal AM, Crowe HM, Nicolau D, Nightingale C, Once-daily aminoglycoside use in patients with Gram-positive endocarditis (Abstract No. 174). Infectious Diseases Society of America, San Francisco, California, September 1995 52a. Nicolau DP, Feng YJ, Wu AHB, Bernstein S, Nightingale CH. Swine model for the evaluation of drug clearance via a novel dialysis system (Abstract No. P39). American Association for Laboratory Animal Science, 46th Annual Meeting, Baltimore, Maryland, October 1995 53a. Berstein SP, Nicolau DP, Wu AHB, Feng YJ, Nightingale CH. CAVH for myoglobin clearance in swine. American Society of Nephrology, 28th Annual Meeting, November 1995 Dr. David Nicolau's Scholarship 60 Shillington AC, Jewell MA, Farley PA. Disease state management model for pneumonia: a multi-center benchmark project (Abstract No. P-281E). American Society of Health-Systems Pharmacists, 30th Annual Midyear Clinical Meeting, Las Vegas, Nevada, December 1995 55a. Aminoglycoside Administration (Abstract No. P-521E). American Society of Health-Systems Pharmacists, 30th Annual Midyear Clinical Meeting, Las Vegas, Nevada, December 1995 56a. Udeh E, Nicolau DP, Chow MSS, Nightingale CH, Quintiliani of a Drug Usage Evaluation Program on Serum Aminoglycoside Concentrations in Patients Receiving Once-Daily Aminoglycosides (Abstract No. P-251E). American Society of Health-Systems Pharmacists, 30th Annual Midyear Clinical Meeting, Las Vegas, Nevada, December 1995 of Subinhibitory Concentrations on the Mortality of Experimental P. aeruginosa sepsis (Abstract No. 9.06). Third International Conference on the Macrolides Azalides and Streptogramins, Lisbon, Portugal, the Bactericidal Activity of Clindamycin Administered Every Eight and Twelve Hours Against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis (Abstract No. 74). American College of Clinical Pharmacy, Annual Meeting, Nashville, Tennessee, August 1996 59a. Owens RC, Patel KB, Oral Ciprofloxacin in Patients with AIDS (Abstract No. A008). American Society for Microbiology, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 1996 60a. Hitt CM, Nightingale CH, Quintiliani R, Nicolau DP. Cost Analysis of Single Dose Ceftriaxone Versus Continuous Infusion Cefotaxime (Abstract No. N09). American Society for Microbiology, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 1996 Dr. David Nicolau's Scholarship 11/7/11 61 61a. Xuan 5S-IgG Immunoglobulin on Experimental Gram-Negative Sepsis (Abstract No. G079). American Society for Microbiology, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Interval on the Efficacy of Penicillin Containing Regimens in Experimental Enterococcal faecalis Endocarditis (Abstract No. B03). American Society for Microbiology, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 1996 63a. Nie L, Treatment of Experimental Pseudomonas aeruginosa Osteomyelitis (Abstract No. A076). American Society for Microbiology, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 1996 64a. Owens RC, Patel KB, Oral Bioavailability of Ciprofloxacin in Patients with AIDS. Connecticut Infectious Diseases Society, 12th Annual Meeting, Southbury, Connecticut, September 1996 Influence of Adjunct Azithromycin Therapy on the Mortality of Experimental Sepsis due to Pseudomonas aeruginosa (Abstract No. 225). 10th Mediterranean Congress of Chemotherapy, Antalya, Turkey, October 1996 66a. Nicolau DP, Tessier PR, Nightingale CH, Quintiliani R. of Ticlopidine Administration in Experimental S. aureus Endocarditis (Abstract No. 222). 10th Mediterranean Congress of Chemotherapy, Antalya, Turkey, October 1996 67a. Lacy MK, Lu W, Xu X, Tessier PR, Quintiliani Nightingale Levofloxacin and Ciprofloxacin against Streptococcus pneumoniae in an In Vitro Model of Infection. The Role of Quinolones in Hospital Pharmacy, Poster symposium presented during American Society of Hospital Pharmacists, 31st Annual Midyear Clinical Meeting, New Orleans, Louisiana, December 1996 Dr. David Nicolau's Scholarship 11/7/11 62 Tobramycin and Selected Beta-Lactams (Abstract No. A-151). American Society for Microbiology, 97th General Meeting, Miami Beach, Florida, May 1997 69a. Nicolau DP. Pharmacokinetic, Pharmacodynamic and Efficacy Considerations in Oral Cephalosporin Therapy Selection (Abstract No. S34). The Role of New Cephalosporins in Rational Antimicrobial Therapy. 8th European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, May 1997 70a. Nicolau DP, Tessier PR, Quintiliani R, Nightingale In Vitro Synergy Between Trovafloxacin and Ceftriaxone or Vancomycin Against S. pneumoniae (Abstract No. 2249). 20th International Congress of Chemotherapy, Sydney, Australia, June-July 1997 Continuous and Intermittent Ceftazidime in ICU Patients with Nosocomial Pneumonia (Abstract No. 4252). 20th International Congress of Chemotherapy, Sydney, Australia, June-July 1997 72a. Lacy MK, Lu W, Ciprofloxacin Against S. pneumoniae in an In Vitro Model (Abstract No. 3278). 20th International Congress of Chemotherapy, Sydney, Australia, June-July 1997 Lacy Efficacy of Trovafloxacin and Ciprofloxacin against S. pneumoniae in a Sepsis Model (Abstract No. 2250). 20th International Congress of Chemotherapy, Sydney, Australia, June-July 1997 Pneumococci (Abstract 3202). 20th International Congress of Chemotherapy, Sydney, Australia, June-July 1997 75a. Owens RC Jr., Keung CH. Effect Rifapentine in Subjects Seropositive for the Human Immunodeficiency Virus (Abstract No. A- Dr. David Nicolau's Scholarship 11/7/11 63 2). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, Trovafloxacin, and Ampicillin Against Isolates of S. pneumoniae with Varying Penicillin Susceptibilities (Abstract No. B-097). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997 77a. Lacy MK, Owens CH. Clarithromycin, Azithromycin, and against (Abstract No. A-43). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, and Ceftriaxone or Vancomycin Against S. pneumoniae with Variable Penicillin Susceptibilities (Abstract No. E-63). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 79a. Ambrose PG, Quintiliani DP. Continuous Infusion Cefuroxime in the Therapy of Community-Acquired Pneumonia (Abstract No. K-4). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997 80a. Lacy M, Nicolau DP, Nightingale CH, A, Vincent J, Quintiliani R. The Pharmacokinetics of Trovafloxacin in Patients with AIDS (Abstract No. A-64). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 81a. Ambrose PG, Quintiliani DP. Continuous Infusion Cefuroxime in the Therapy of Community-Acquired Pneumonia. (Abstract No. 76). 1997 Annual Meeting, American College of Clinical Pharmacy, Phoenix, Arizona, November 9-12, 1997 82a. Lacy M, Nicolau DP, Nightingale CH, Vincent J, Quintiliani R. The Pharmacokinetics of Trovafloxacin in Patients with AIDS (Abstract No. Dr. David Nicolau's Scholarship 11/7/11 64 92E). 1997 Annual Meeting, American College of Clinical Pharmacy, Phoenix, Arizona, November 9-12, 1997 83a. Klepser ME, Patel KB, Nightingale CH. Comparison of the Bactericidal Activity of Intermittent and Continuous Infusion Vancomycin Dosing Regimens against Methicillin-Resistant S. aureus and E. faecalis (Abstract No. 72). 1997 Annual Meeting, American College of Clinical Pharmacy, Phoenix, Arizona, November 9-12, 1997 84a. Owens RC Jr., Typical Community Acquired Tract (TCART) Pathogens (Abstract No. 73). 1997 Annual Meeting, American College of Clinical Pharmacy, Phoenix, Arizona, November 9-12, 1997 85a. Tobramycin and Selected Beta-Lactam Agents (Abstract No. 81E). 1997 Annual Meeting, American College of Clinical Pharmacy, Phoenix, Arizona, November 9-12, 1997 86a. Owens RC Jr., Keung CH. Effect Rifapentine in Subjects Seropositive for the Human Immunodeficiency Virus (Abstract No. 188E). 1997 Annual Meeting, American College of Clinical Pharmacy, Phoenix, Arizona, November 9-12, 1997 87a. Lacy MK, Owens R, Nightingale CH. A Comparison of and Multidose Administration of Clarithromycin, Azithromycin, and Cefuroxime Axetil against S. pneumoniae (Abstract International Conference on the Macrolides, Azalides, Streptogramins and Ketolides. Barcelona, Nicolau DP, Nightingale CH, Geffken A, Vincent J, Quintiliani R. The Pharmacokinetics of Trovafloxacin in Patients with AIDS (Abstract No. T-119). 2nd European Congress of Chemotherapy and 7th Biennial Conference on Antiinfective Agents and Chemotherapy, Hamburg, Germany, May 10-13, 1998. 89a. DP, Lacy MK, McNabb JC, Nightingale CH. Continuous versus Intermittent Administration of Ceftazidime in Intensive Care Unit Patients Dr. David Nicolau's Scholarship 11/7/11 65 with Nosocomial Pneumonia (Abstract No. K-107). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998 90a. Xuan D, Nicolau DP, Bow of Endotoxin Induction of TNF- in Human Monocyte-enriched Peripheral Blood Mononuclear cells with the 5S Fragment of Immunoglobulin G (Abstract No. G-040). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998 91a. McNabb and Clarithromycin for MAC Prophylaxis in AIDS Patients (Abstract No. I-142). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998 Lacy M, Tessier PR, Comparison of Vancomycin Pharmacodynamics Against Methicillin-Resistant Staphylococcus Isolates with 1 Gram Every 12 or 24 Hour Dosing (Abstract No. 63). 1998 Annual Meeting, American College of Clinical Pharmacy, Cincinnati, Ohio, November 8-11, 1998 93a. in AIDS Patients Requiring Mycobacterium avium complex (MAC) Prophylaxis (Abstract No. 255-Sa). 36th Annual Meeting of the Infectious Diseases Society of America, Denver, Colorado, November 12-15, 1998 94a. Ambrose PG, versus Ceftazidime (TAZ) in Intensive Care Unit (ICU) Patients with Hospital-Acquired Pneumonia (HAP) (Abstract No. 666-Fr). 36th Annual Meeting of the Infectious Diseases Society of America, Denver, Colorado, November 12-15, 1998 95a. McNabb JC, Comparison of Azithromycin Leukocyte Disposition in Healthy Volunteers versus Volunteers with AIDS (Abstract No. B 41). Second International Meeting on the Therapy of Infections, Florence, Italy, November 18-21, 1998 Dr. David Nicolau's Scholarship Patients Requiring Mycobacterium avium complex Prophylaxis (Abstract No. 74E). International Congress on Clinical Pharmacy, Orlando, Florida, April 11-14, 1999 97a. McNabb JC, Comparison of Azithromycin Leukocyte Disposition in Healthy Volunteers versus Volunteers with AIDS (Abstract No. 73E). International Congress on Clinical Pharmacy, Orlando, Florida, April 11-14, 1999 98a. Nicolau DP, against Streptococcus pneumoniae Using the Pharmacokinetic Profile in Children (Abstract No. 1777). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999 99a. Lu J, Xuan in Hospitalized Patients (Abstract No. 1008). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999 100a. Xuan D, Nicolau DP, Bow L, Quintiliani of the Kinetic Profile of Endotoxin-Mediated TNF- Induction in a Rat Endotoxin Septic Shock Model (Abstract No. 0264). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, and In Vivo Influence of Adjunct Clarithromycin on the Treatment of Mucoid Pseudomonas aeruginosa (Abstract No. G-0786). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999 and Pharmacoeconomic Evaluation of Ticarcillin-Clavulanate Administered either as Continuous or Intermittent Infusion with Once-Daily Gentamicin (Abstract No. A-1192). 39th Interscience Conference on Dr. David Nicolau's Scholarship 11/7/11 67 Antimicrobial Agents and Chemotherapy, San Francisco, Nicolau DP, in the Treatment of Mucoid Pseudomonas aeruginosa Pneumonia (Abstract No. 787). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, McNabb JC, Cost-Effectiveness of Ceftazidime in Nosocomial Pneumonia given as a Continuous Infusion vs. Intermittent Infusion (Abstract No. 1864). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, and In Vivo Influence of Adjunct Clarithromycin on the Treatment of Mucoid Pseudomonas aeruginosa (Abstract 91E). Annual Meeting American College of Clinical Pharmacy, Kansas City, Missouri, October 24-27, 1999 106a. and Pharmacoeconomic Evaluation of Ticarcillin-Clavulanate Administered either as Continuous or Intermittent Infusion with Once-Daily Gentamicin (Abstract 91E). Annual Meeting American College of Clinical Pharmacy, Kansas City, Missouri, October 24-27, 1999 107a. Xuan D, Nicolau D, Study of Gentamicin after Once-Daily Dosing in Hospitalized Patients (Abstract No. 3411). American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, Louisiana, November 14-18, 1999 Meropenem in Adult Cystic Fibrosis Patients (Abstract 15). 1999 Annual Meeting of Infectious Diseases Society of America, November 18-21, 1999 109a. McNabb JC, Bactericidal Activity of Trovafloxacin and Ciprofloxacin alone and in combination with Cefepime against P. aeruginosa (Abstract 100363). 1999 Annual Meeting of Infectious Diseases Society of America, November 18-21, 1999 Dr. David Nicolau's Scholarship 11/7/11 68 110a. Grant Quintiliani R, Fitzgerald J, Nightingale CH. Determination of Potential and Extent of Drug-Drug Interaction of Oral Levofloxacin and Oxycodone (Abstract 100692). 1999 Annual Meeting of Infectious Diseases Society of America, November 18-21, 1999 111a. Grant EM, Ambrose Meropenem Solution in a Portable Refrigerated Infusion Pump (Abstract 5). 1999 Annual Meeting of Infectious Diseases Society of America, November 18-21, 1999 and In Vivo Influence of Adjunct Clarithromycin on the Treatment of Mucoid Pseudomonas aeruginosa (Abstract in Treatment of Mucoid Pseudomonas aeruginosa Pneumonia (Abstract No. 11.16). 5th the Macrolides, Azalides, Streptogramins, Oxazolidinones, Seville, virologic outcome in minority/IVDU clinic population (Abstract No. TuOrB416), World AIDS Conference, Durban, South Africa, July 9, 2000 Streptococcus pneumoniae in the neutropenic thigh infection model (Abstract No. 290), 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000 Exposure of Moxifloxacin or Levofloxacin Using a Rabbit Tissue Cage Model (Abstract No. 286). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000 Dr. David Nicolau's Scholarship 11/7/11 Quintiliani Caused by Pseudomonas aeruginosa (Abstract No. 742). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000 118a. Grant EM, Nicolau DP, Gatifloxacin (Abstract No. 2272). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000 119a. Kim MK, Pneumococcal Pneumonia Model (Abstract No. 1019). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000 Extended Interval Piperacillin/Tazobactam (Abstract No. 2249). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000 121a. DP, Onyeji of Adjunctive Treatment with Combined Cytokines in a Neutropenic Mouse Model of Multidrug-Resistant Enterococcus faecalis Septicemia (Abstract 322). Annual Meeting American College of Clinical Pharmacy, Los Angeles, California, November 6, 2000 122a. Mattoes HM, Banevicius MA, 16th Annual Meeting, Connecticut Infectious Diseases Society, Southbury, Connecticut October 2000 123a. Profile of High Dose Extended Interval Piperacillin/Tazobactam. 16th Annual Meeting, Connecticut Infectious Diseases Society, Southbury, Connecticut October 2000 Efficacy and Pharmacoeconomics of Piperacillin/Tazobactam Administered by Continuous versus Intermittent Infusion (Abstract RP-323). American Society of Health- Dr. David Nicolau's Scholarship 11/7/11 70 System Pharmacists, 35th Annual Midyear Clinical Meeting, Las Vegas, Nevada, December 2000 125a. Kim MK, Zhou W, Tessier PR, a Murine Pneumococcal Pneumonia Model (Abstract No. P9.015). 22nd International Congress of Chemotherapy, Amsterdam, The Netherlands, June 30 - July 3, 2001 126a. Mattoes HM, Capitano 950). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 22-25, 2001 127a. MK, Banevicius during Continuous Veno-Venous Hemofiltration (CVVH) With or Without Dialysis (Abstract No. 935). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Pharmacist-Managed Automatic Intravenous (IV) to Oral (PO) Conversion Program (Abstract No. 391). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Influence of Methicillin-Resistance on the Cost of Infection Management due to Staphylococcus Aureus in a Long-Term Care Facility (Abstract No. 397). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 22-25, 2001 130a. (Abstract No. 2097). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 22-25, 2001 A Population Dr. 11/7/11 Approach (Abstract No. 2185). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Resistant Streptococcus Model (Abstract No. 1656). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 22-25, 2001 133a. Simpson IN, Di Modugno E, Jabes D, Nicolau D. Oxapenem AM-112: In vivo efficacy alone and in combination with ceftazidime in animal models of infection, involving pathogens producing Class A and Class C -lactamases (Abstract No. F-385). 41st Interscience Conference on Antimicrobial Agents Chemotherapy, Chicago, Efficacy and Pharmacoeconomics of Piperacillin/Tazobactam Administered by Continuous versus Intermittent Infusion (Abstract 139E). Annual Meeting American College of Clinical Pharmacy, Tampa, Florida, October 21-24, Automatic Intravenous to Oral Conversion Program (Abstract No. 290E). Annual Meeting American College of Clinical Pharmacy, Tampa, Florida, October 21-24, Piperacillin/Tazobactam against Pseudomonas aeruginosa using Monte Carlo Analysis (Abstract No. 229E). Annual Meeting American College of Clinical Pharmacy, Tampa, Florida, October 21-24, 2001 137a. Capitano Influence of Methicillin-Resistance on the Cost of Infection Management due to Staphylococcus Aureus in a Long-Term Care Facility (Abstract No. 185E). Annual Meeting American College of Clinical Pharmacy, Tampa, Florida, October 21-24, 2001 138a. Xuan Mice: A Azalides, Streptogramins, Ketolides and David Nicolau's Scholarship 11/7/11 72 139a. Kim ABT-773 in a Murine Pneumococcal Pneumonia Model (Abstract No. 5.05). Conference Azalides, Streptogramins, Ketolides DP, Holz ER. Vitreous Penetration of Orally Administered Gatifloxacin in Humans (Abstract No. XX). Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida May 2002 141a. Nicolau DP, Simpson IN, Urch JC. Oxapenem XOB (AM-114): In vitro activity alone and in combination with amoxycillin or cefaclor against community-acquired respiratory tract pathogens (Abstract No. 222). 12th European Congress of Clinical Microbiology and Infectious Disease, Milan, Italy, April 24-27, 2002 142a. Zervos SF, Eng RHK, Hiltz A, Kuyumjian AG, McDaniel A, Hogan P, Lubowski TJ. Impact of Fluoroquinolone Usage on Pathogen Susceptibility: A 10 year multicenter Evaluation (Abstract No. A-7). 102nd General Meeting of the American Society of Microbiology, Salt Lake City, Utah, May 2002 143a. Capitano B, Mattoes HM, Shore DP. Bonchopulmonary Adults Undergoing Diagnostic Bronchoscopy (Abstract No. P2681). European Respiratory Society Annual Congress, Stockholm, Sweden, September 14-18, 2002 144a. Model (Abstract No. A1-1271). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 29, 2002 145a. Dandekar a 3h Infusion (Abstract No. A1-1388). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 29, 2002 Dr. David Nicolau's Meropenem (MEM) in Gram- Negative Bacteria (Abstract No. A1-637). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 28, 2002 147a. Dandekar Daptomycin Against and Methicillin Resistant S. aureus in a Murine Thigh Infection Model (Abstract No. A1-1270). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 29, 2002 148a. Kuti JL, Liposomal Amphotericin B (L-AmB) in the Treatment of Fungal Infections (Abstract No. O-1000). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 28, 2002 149a. Li C, Nicolau DP, -lactamase Inhibitors against -lactamase Inducible Pseudomonas aeruginosa Infections (Abstract No. A1-1255). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 29, 2002 150a. Simpson IN, Urch CJ, Jabes D, Candiani G, Nicolau DP. AM-114: Chemistry of a novel orally absorbed broad-spectrum oxapenem -lactamase inhibitor. (Abstract No. P1003). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, Pseudomonas aeruginosa (PSA) (Abstract No. 100319). 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, Illinois, October 24-27, 2002 152a. Zervos M, Hershberger E, Nicolau D, Ritchie D, Blackner L, Coyle E, Donnelly A, Eckel S, Eng R, Hiltz A, Kuymjian A, McDaniel A, Hogan P, Lubowski T. A 10 Year Multicenter Study of the Association Between Quinolone (Q) Susceptibility and Quinolone Density Rate (QDR) Using Baseline to Endpoint Dr. David Nicolau's Scholarship 11/7/11 74 (BE) and Trend-line Analyses (TL) (Abstract No. 101028). 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, Illinois, October 24-27, 2002 153a. Daptomycin Against and Methicillin Resistant S. aureus in a Murine Thigh Infection Model (Abstract No. 156E). 2002 Annual Meeting American College of Clinical Pharmacy, Albuquerque, New Mexico, October 20-23, 2002 154a. Blister Focus on Healing and Blister Resolution (Abstract No. 257E). 2002 Annual Meeting American College of Clinical Pharmacy, Albuquerque, New Mexico, October 20-23, 2002 155a. Maglio D, Nicolau DP, Teng R, Thyrum PT. Penetration of Meropenem (MEM) into Human Skin Blister Fluid (Abstract No. 155E). 2002 Annual Meeting American College of Clinical Pharmacy, Albuquerque, New Mexico, October 20-23, 2002 156a. Li C, Nicolau DP, Ticarcillin and Clavulanate in Rabbit Serum and Tissue Cage Fluid (TCF) by HPLC (Abstract No. W4013). American Association of Pharmaceutical Scientists, 2002 Annual Meeting & Exposition, Toronto, Ontario, Canada, November 10-14, 2002 157a. Capitano B, Mattoes H, Shore E, O'Brien A, Braman S, Sutherland C, Nightingale C, Nicolau D. Intrapulmonary Disposition of Multiple Dose Moxifloxacin, Levofloxacin and Azithromycin in Older Adults (Abstract No. 4234). 2003 American Thoracic Society International Conference, Seattle, Cystic Fibrosis (Abstract No. 2135). 2003 American Thoracic Society International Seattle, Washington, May 13-16, 2003. TG, Chugtai Secretions of Patients with Ventilator-Associated Tracheobronchitis Dr. David Nicolau's Scholarship 11/7/11 75 (Abstract No. p 368). 2003 American Thoracic Society International Conference, Seattle, Washington, Intravenous to Oral Conversion Programs for Anti-Infectives in the United States (Abstract No. 197). 2003 Spring Practice and Research Forum of the American College of Clinical Pharmacy, Palm Springs, California, April 29, 2003. 161a. LI C, Nicolau DP, Nightingale CH. Simultaneous Piperacillin and Tazobactam Concentrations in Rabbit Serum and Tissue Cage Fluid (Abstract No. 124). 2003 Spring Practice and Research Forum of the American College of Clinical Pharmacy, Palm Springs, California, April 29, 2003. 162a. Nicolau Telithromycin in a Murine Infection Model (Abstract No. P1620). 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, Scotland, May 13, 2003. 163a. Dandekar PK, Williams P, of with Ribosomal Mutations (Abstract No. A-304). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14, 2003 164a. Dandekar PK, Williams P, Tessier Assessment against S. Mutations Using Time-Kill Methodology (Abstract No. E-1525). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 16, 2003 165a. Dandekar PK, Tessier PR, Williams P, DP. Determination of the Pharmacodynamic Profile of Daptomycin against S. pneumoniae with Varying Susceptibility to Penicillin in a Murine Thigh Infection Model (Abstract No. A-311). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14, 2003 166a. Fetterly GJ, Ong C, of Pharmacokinetics (PK) of Oritavancin (ORI) in Plasma and Blister Fluid in Normal Healthy Volunteers (Abstract No. A-18). 43rd Dr. David Nicolau's Scholarship 11/7/11 76 Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14, 2003 167a. Maglio D, Ong C, Banevicius MA, Nightingale CH, Lack of Impact the in vivo No. A-1317). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 16, 2003 168a. Li C, Nicolau DP, Lister L, Clavulanate (Abstract No. C1-667). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 15, 2003 169a. Using An In-Vitro Model (Abstract No. A-1162). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003 Attainment between Healthy Subject and patient Data using Monte Carlo Simulation (Abstract No. A-9). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, MYSTIC Antibiogram (OPTAMA) - North America (NA) 2002 (Abstract No. A-7). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Kuti JL, Nightingale (MEM) Dosing Protocol Based on Pharmacodynamic (PD) Concepts (Abstract No. A-1364). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 16, 2003 173a. Zhang C, Nightingale CH, Nicolau DP. Reverse Phase High Performance Liquid Chromatographic Method for Determination of Moxifloxacin in special growth media. 6th Drug Analysis Conference, Chinese Pharmaceutical Journal and SHINADZU Cup Meeting, Peking, China, September 2003 Dr. David Nicolau's Scholarship 11/7/11 77 174a. Nicolau DP, Jenkins SG. and multi-drug resistance among isolates of Streptococcus pneumoniae from the USA during PROTEKT US Year 2 (2001-2002) (Abstract No. 203). 41st Annual Meeting Infectious Diseases Society of America, San Diego, California, October 10, 2003 175a. of Pseudomonas aeruginosa Pneumonia in Non-Neutropenic Host (Abstract No. 104). 2003 Annual Meeting American College of Clinical Pharmacy, Atlanta, Georgia, November 2-5, 2003 176a. Ong CT, Pharmacodynamic Characterization of Meropenem and its Impact on the Selection of Resistance Among Pseudomonas aeruginosa (Abstract No. 105). 2003 Annual Meeting American College of Clinical Pharmacy, Atlanta, Georgia, November a Meropenem Dosing Protocol Based on Pharmacodynamic Concepts (Abstract No. 102E). 2003 Annual Meeting American College of Clinical Pharmacy, Atlanta, Georgia, November 2-5, - South 2002 (Poster IH 101). Congresso Brasileiro de Microbiologia, Florian\u00f3polis PB, Nicolau Zitt MJ. Start Treatment with Appropriate Antibiotic Respiratory Therapy: An Expert Panel Discussion (Abstract No. 1018). Annual Meeting of the American Academy of Allergy, Asthma & Immunology, San Francisco, California, March 2004 180a. pneumoniae (Abstract No. 3567, E19). 2004 American Thoracic Society International Conference, Orlando, Florida, May 23-24, 2004. 181a. Brown S, Nicolau D, Patel M. Multi-drug resistance among isolates of Streptococcus pneumoniae from respiratory and blood culture sources in the US: Data from PROTEKT US Year 2 (2001-2002) (Abstract No. A46, E9). 2004 Dr. David Nicolau's Scholarship 11/7/11 78 American Thoracic Society International Conference, May Escherichia coli (EC) and Klebsiella pneumoniae (KP) in Europe, 2002 (Abstract No. P1105). 14th European Congress of Clinical Microbiology and Infectious Disease, Prague, Czech Republic, May 1-4, 2004. 183a. the MYSTIC Antibiogram (OPTAMA) - Acinetobacter sp. (AS) and P. aeruginosa (PSA) in Europe, 2002 (Abstract No. P1104). 14th European Congress of Clinical Microbiology and Infectious Disease, Prague, Czech Republic, May 1-4, 2004. 184a. for Empiric Therapy in Surgical Wound Infections - A Report from the OPTAMA Program (Abstract No. SE215). 90th Annual Clinical Congress of American College of Surgeons, New Orleans, Louisiana, October 10-14, 2004. 185a. for the Empiric Treatment of Secondary Peritonitis - A Report from the OPTAMA Program (Abstract No. SE167). 90th Annual Clinical Congress of American College of Surgeons, New Orleans, Louisiana, October 10-14, 2004. 186a. Kuti JL, hemofiltration (CVVH): a report from the 2003 OPTAMA Program (Abstract No. 316). Infectious Diseases Society of America, Boston, MA, September 30-October 3, 2004. a report from the OPTAMA Program (Abstract No. 314). Infectious Diseases Society of America, Boston, MA, September 30-October 2004. in pediatric patients: a report from the OPTAMA Program (Abstract No. 315). Infectious Diseases Society of America, Boston, MA, September 30-October 3, 2004. Dr. David Nicolau's Scholarship Treatment of Nosocomial Pneumonia Program (Abstract No. 320). Infectious Diseases Society of America, Boston, MA, September 30-October 3, and Microbiological Response (MR) of Different Antibiotic Classes on Extended Spectrum -lactamase (ESBL) Producing Pathogens in a Large Teaching Center (Abstract No. 443). Infectious Diseases Society of America, Boston, MA, September 30-October 3, 2004. pediatric patients: a report from the OPTAMA Program (Abstract No. 266E). American College of Clinical Pharmacy, 2004 Annual Meeting, Dallas, TX, October 24-27, 2004 192a. Li C, Dana A, Nicolau DP. Population Pharmacokinetics of Continuous and Intermittent Infusion Piperacillin/Tazobactam in Patients with Complicated Intra-abdominal Infection (Abstract No. 375). World Conference - Dosing of Anti-Infectives, N\u00fcrnberg, Germany, September 9-11, CH, Nicolau DP. HPLC Determination of Tigecycline in Human No. 376b). World Conference - Dosing of Anti-Infectives, N\u00fcrnberg, Germany, September Pseudomonas aeruginosa do not translate to in vivo failure in Efficacy or emergence of resistance to meropenem, imipenem, or cefepime (Abstract No. A-1867). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., October 30 - November 2, 2004 195a. Grillot AL, Stamos D, Grossman T, Bi Y, Carver M, Deininger D, Drumm J, Fowlie A, Gross C, Letiran A, Liao Y, Ma J, Mani N, Moore J, Nicolau D, Olson E, Parsons J, Partaledis J, Perola E, Ronkin S, Tang Q, Tian SK, Tessier P, Wang T, Wei Y, Zhang H, Charifson P. A New Class of Dual Targeting Inhibitors of GyrB and ParE (Abstract No. F-1951). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., October 30 - November 2, 2004 Dr. David Nicolau's Scholarship 11/7/11 80 196a. Maglio Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., October 30 - November 2, 2004 197a. Maglio D, Sun HK, Patel T, Banevicius DP, Arya New Ketolide EP-13420 in a Murine S. pneumoniae (SPN) Pneumonia Model (Abstract No. F-1407). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., October 30 - November 2, 2004 198a. Kotapati Spectrum -lactamase Producing Klebsiella sp. And Escherichia coli Infections Treated with Cefepime (Abstract No. A-1590). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., October 30 - November 2, 2004 199a. Sun HK, Ong CT, Umer A, Harper D, Pharmacokinetic Profile of Tigecycline in Serum and Blister Fluid After Multiple Intravenous Administrations in Healthy Adults (Abstract No. A-12). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., October 30 - November 2004 No. A-141). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., October 30 - November 2, 2004 201a. Ong CT, Babalola No. A-1303). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., October 30 - November 2, 2004 202a. Sun HK, Kuti JL, Nicolau Nosocomial Pneumonia: A Report from the OPTAMA Program (Abstract No. P902). 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005 Dr. David Nicolau's Scholarship 11/7/11 81 203a. Kuti Nicolau DP. Comparison of Pharmacodynamic Target Attainment (TA) Calculated by Monte Carlo Simulation with Microbiological Response (MR) for Two Carbapenems in the Treatment of Complicated Skin and Skin Structure Infections (Abstract No. O122). 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005 204a. Ludwig intravenous antimicrobials against Pseudomonas aeruginosa in Hungarian hospitals - A report from the OPTAMA Program (Abstract No. P904). 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005 with activity against MRSA (Abstract No. P1573). 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005 206a. Duchin K, Sun H, Shaw JP, Nicolau D. Pharmacokinetics and Tissue Penetration of Telavancin in Healthy Volunteers (Abstract No. P898). 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April Pediatric Meningitis - A Report from the OPTAMA Program (Abstract No. 513). Pediatric Academic Societies' Annual Meeting, Washington, DC, May 14-17, 2005 208a. Nicolau Sutherland Pichichero ME. Pharmacokinetics of Cefprozil in Plasma and Middle Ear Fluid (MEF) of Children Undergoing Treatment for Acute Otitis Media (AOM) (Abstract No. A-17). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, December 2005 209a. Lau W, Mercer D, Itani K, Nicolau DP, Kuti JL, Mansfield D, Dana A. A Randomized Comparative Study of Piperacillin/Tazobactam (TZP) Continuous (CI) vs. Intermittent Infusion (II) for Complicated Intra-Abdominal Infection (Abstract No. L-581). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, December 2005 Dr. David Nicolau's Scholarship 11/7/11 (ESBL) Producing Bacteria on Hospital Cost: a Case Control Study (Abstract No. O-174). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, December 2005 (ESBL) Producing Bacteria on Initial Antibiotic Therapy: A Case Controlled Study (Abstract No. K-1290). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, December 2005 212a. Lee SY, Tessier PR, Murphy Novel Pneumococcal Pneumonia Model (Abstract No. F-2044). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, December 2005 213a. DeRyke CA, Xu D, Nicolau DP. Evaluation of Bacterial Kill when Modeling the Bronchopulmonary Profile of Moxifloxacin (MOX) and Levofloxacin (LVX) against (SPN) (Abstract No. A-453). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, December 2005 214a. Sun HK, Du X, DeRyke CA, (LVX) against ParE Containing Isolates of S. Pneumoniae (SPN) (Abstract No. A-454). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, December 2005 215a. Li C, Du X, (PD) of Meropenem Adult Patients with Lower Respiratory Tract Infections (LRTI) (Abstract No. A-1147). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New SY, No. A-1151). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, December 2005 217a. DeRyke CA, Xu D, Nicolau DP. Evaluation of Bacterial Kill when Modeling the Bronchopulmonary Pharmacokinetic Profile of Moxifloxacin (MOX) and 11/7/11 83 Levofloxacin (LVX) against parC Containing Isolates of S. pneumoniae (SPN) (Abstract No. 185E). American College of Clinical Pharmacy, 2005 Annual Meeting, San Francisco, CA, October 23-26, 2005 218a. Sun HK, Nicolau DP, Kuti JL. Resource Utilization and Outcomes of Adults Admitted to a Tertiary Hospital with Community Acquired Pneumonia (CAP) Caused by Streptococcus pneumoniae (SP) (Abstract No. 271). American College of Clinical Pharmacy, 2005 Annual Meeting, San Francisco, CA, October 23-26, 2005 (ESBL) Producing Bacteria on Initial Antibiotic Therapy: A Case Controlled Study (SP) (Abstract No. 274E). American College of Clinical Pharmacy, 2005 Annual Meeting, San Francisco, CA, October 23-26, 2005 220a. DeRyke CA, Kuti JL, Mansfield D, Dana Nicolau DP. Pharmacoeconomics of Continuous versus Intermittent Infusion Piperacillin/tazobactam for the Treatment of Hospitalized Patients with Complicated Intra-abdominal Infection (Abstract No. RP76). American Society of Hospital Pharmacists, 40th Annual Midyear Clinical Meeting, Las Vegas, Nevada, December 2005 (ESBL) producing Escherichia coli and Klebsiella spp from the MYSTIC Program in Brazil. (Abstract No. P1550). 16TH European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 2006 222a. Stein GE, Schooley S, (Abstract No. P1533). 16TH European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 2006 223a. Wong SL, Shaw JP, Nicolau DP, Barrierre S, Kitt M, Goldberg M. Pharmacokinetic Modeling of Telavancin Penetration into Skin Blister Fluid (Abstract No. A2786). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2006 Zhanel Activity Molecularly Characterized Multi-Drug Resistant Extended Spectrum -lactamase (ESBL) producing E. coli Using Dr. David Nicolau's Scholarship 11/7/11 84 an In Vitro Model. (Abstract No. A1679). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006 225a. Deryke CA, Fan HW, Banevicius MA, Nicolau In Vivo Efficacy of Human A0011). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San CA, September 27-30, 2006 226a. Deryke CA, Nicolau DP. Is All Time Above the Minimum Inhibitory Concentration (MIC) the Same: Implications for In Vivo Modeling. (Abstract No. A0005). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006 227a. Eagye Kuti JL. Differing Epidemiology and Resistance Patterns of Respiratory Isolates (RI) from Three Intensive Care Units (ICUs) within the Same Institution. (Abstract No. K0259). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, Superinfection (SI) on Hospital Length of Stay (LOS) and Costs in Patients with Ventilator-Associated Pneumonia (VAP). (Abstract No. K0286). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006 229a. Nicolau DP, Levofloxacin 750 mg Once-daily in Patients with Exacerbation of Chronic Bronchitis. (Abstract No. A0332). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San 27-30, Deryke CA, Pharmacodynamic No. D0703). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006 Dr. David Nicolau's Scholarship 11/7/11 85 231a. In Vivo Pharmacodynamic Profiling of API-1252 Against Staphylococcus aureus in a Murine Thigh Model. (Abstract No. D0703). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006 232a. Deryke CA, and without Co-Administration of Gentamicin Against Isolates of Staphylococcus aureus and Enterococcus species. (Abstract No. A0629). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San as a Surrogate Marker for Antibiotic Efficacy in Cost-Effectiveness Analyses (CEA). (Abstract No. O1465). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006 234a. Tessier PR, Fan HW, Tanaka of PTK0796 against S. pneumoniae Murine Pneumonia Model). (Abstract No. F1-1973). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 27-30, Assess Tigecycline (TG) Predicted Efficacy Compared with Other Antibiotics for Hospital-Acquired Pneumonia (HAP). (Abstract No. 213) 44th Annual Meeting of Infectious Diseases Society of America, Toronto, Canada, October 12-15, (TG) Compared with Other Antibiotics for Complicated Skin and Soft Tissue Infections (SSTI). (Abstract No. P1-020). 10th Western Pacific Congress on Chemotherapy and Infectious Diseases, Fukuoka International Congress Center, Fukuoka, Japan, December 3-6, 2006 237a. Lee SY, of Simulating Lining Fluid Concentrations against Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA). (Abstract No. P2-027). 10th Western Pacific Congress on Chemotherapy and Dr. David Nicolau's Scholarship 11/7/11 86 Infectious Diseases, Fukuoka International Congress center, Fukuoka, Japan, December 3-6, 2006 238a. Kiffer C, Kuti D. Pharmacodynamic comparison of linezolid, teicoplanin, and vancomycin against clinical isolates of Staphylococcus aureus and coagulase negative staphylococci collected from hospitals in Brazil. (Abstract No. P1375). 17th European Congress of Clinical Microbiology and Infectious Diseases - 25th International Congress of Chemotherapy, Munich, Germany, March 31 - April 3, 2007 239a. Banevicius MA, Kaplan N, Vaughan D, Nicolau DP. Comparative Dose Studies of API-1252 and Linezolid Against Hospital-Acquired (HA) and Community-Acquired (CA) Methicillin-Resistant Staphylococcus aureus (MRSA) in a Murine Thigh Model. (Abstract No. O455). 17th European Congress of Clinical Microbiology and Infectious Diseases - 25th International Congress of Chemotherapy, Munich, Germany, March 31 - April 3, 2007 240a. Eagye KJ, Nicolau DP, Heilmann K, Gallagher G, Abramson M. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004. (Abstract No. P1813). 17th European Congress of Clinical Microbiology and Infectious Diseases - 25th International Congress of Chemotherapy, Munich, Germany, March 31 - April 3, 2007 Recommended for Secondary Peritonitis, including the novel agent Tigecycline using Global Resistance Data. (Abstract No. O421). 17th European Congress of Clinical Microbiology and Infectious Diseases - 25th International Congress of Chemotherapy, Munich, Germany, March 31 - April 3, 2007 242a. Kim A, Sutherland Infusion? (Abstract No. P1372). 17th European Congress of Clinical Microbiology and Infectious Diseases - 25th International Congress of Chemotherapy, Munich, Germany, March 31 - April 3, 2007 243a. St. Germain for the Empiric Treatment of Acute Otitis Media in Children (Abstract No. 642, S07). 16th Pediatric Pharmacy Conference and Annual Meeting, Portsmouth, Virginia, September 2007 Dr. David Nicolau's Scholarship 11/7/11 87 244a. Kuti JK, Nicolau DP. Impact of Inadequate Antibiotic Therapy (IAT) on Hospital Length of Stay (LOS) in Patients with Complicated Skin and Skin Structure Infections (cSSSI). (Abstract No. K-1256). 47th Interscience Conference on Antimicrobial Agents 17-20, 2007 245a. Eagye KJ, Nicolau DP. Incidence of Infection and Impact on Hospital Length of Stay (LOS) and Costs in Patients Undergoing Elective Colorectal Surgery (ECS). (Abstract No. K-1127). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007 246a. Kim A, Banevicius MA, Nicolau DP. In Efficacy of Doripenem aeruginosa. (Abstract No. A-32). 47th Interscience Conference on Antimicrobial and Chemotherapy, Chicago, IL, September 17-20, 2007 247a. Banevicius MA, Kaplan N., Nicolau DP. Studies of API-1252 and Linezolid Against Community-Acquired Methicillin-Resistant Staphylococcus aureus in a Murine Pneumonia Model. (Abstract No. F1-930). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007 248a. Laohavaleeson S, Lolans K, Quinn Cefepime Resistant-Ceftazidime Susceptible Pseudomonas aeruginosa among Clinical Isolates from a US Hospital. (Abstract No. C2-1501). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2007 Telavancin (TLV) versus Vancomycin (VAN) for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI). (Abstract No. O-1871). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2007 250a. S, Tessier PR, Nicolau of Ceftobiprole in Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus. (Abstract No. A-38). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007 Dr. David Nicolau's Scholarship Telavancin versus Vancomycin for the Treatment of Complicated Skin and Skin Structure Infections. (Abstract No. 185E). American College of Clinical Pharmacy, 2007 Annual Meeting, Denver, CO, October 14-17, 2007 252a. Kim A, Nicolau DP, Kuti JL. Hospital Costs and Outcomes of Patients Discharged with a Diagnosis of Pulmonary Aspergillosis in the United States. (Abstract No. 189). American College of Clinical Pharmacy, 2007 Annual Meeting, Denver, CO, October 14-17, 2007 253a. Kim A, Banevicius MA, Nicolau DP. In Efficacy of Doripenem Human Simulated Exposures against Pseudomonas aeruginosa. (Abstract No. 109E). American College of Clinical Pharmacy, 2007 Annual Meeting, Denver, CO, October 14-17, 2007 254a. Kuti JL, Outcomes of an Empiric Antibiotic Algorithm (EAA) for Ventilator Associated Pneumonia (VAP) that Considers Local MIC Distributions and Pharmacodynamics (Abstract No. 1026). 45th Annual Meeting of Infectious Diseases Society of America, San Diego, CA, October 4-7, 2007 255a. Kim A, Sakoulas G, of Vancomycin versus Linezolid against Methicillin-Resistant Staphylococcus aureus Strains in New York (Abstract No. RP18) American Society of Hospital Pharmacists, 42nd Annual Midyear Clinical Meeting, Las Vegas, Nevada, December 2-6, 2007 256a. Crandon coli, Klebsiella spp., and Pseudomonas aeruginosa isolates in USA Hospitals. (Abstract No. 44). American College of Clinical Pharmacy, 2008 Spring Research and Practice Forum, Phoenix, AZ, April 5 - 9, 2008 257a. Kim A, Koomanachai Nicolau DP. Pneumonia). (Abstract No. A-041). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008 Dr. David and Klebsiella pneumoniae in a Murine Thigh Model. (Abstract No. A-040). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October Kuti JL, Nicolau Diseases Society of America/American Thoracic Society (IDSA/ATS) Criteria in Predicting Severe Community Acquired Pneumonia (CAP) Caused by Streptococcus pneumoniae (SP. (Abstract No. L-677). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008 with Reduced Susceptibility to Piperacillin-Tazobactam (TZP) at 39 Hospitals. (Abstract No. C2-201). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, (Abstract No. A-010). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008 262a. Nicasio Pathway (CP) for Empiric Antibiotic Choice in Patients with Ventilator Associated Pneumonia (VAP). (Abstract No. K-490). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008 263a. Nicasio High Dosed-Cefepime in Adult Critically-Ill Patients with Ventilator Associated Pneumonia. (Abstract No. A-1880). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008 Dr. David Nicolau's Scholarship 11/7/11 90 264a. Kim A, Suecof LA, Sutherland Gao L, Kuti JL, Nicolau DP. Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers by In Vivo Microdialysis. (Abstract No. A-1884). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, Resistant Pseudomonas aeruginosa (MRP). (Abstract No. K-3492). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008 266a. Tessier PR, Love W, Hayter DP. A novel XF antibacterial, DPD-207, against Staphylococcus aureus (SA) in a Murine Thigh Infection Model). (Abstract No. F1-3969). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October Diverse Staphylococcus aureus in a Murine Thigh Model. (Abstract No. A-987). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, -lactams using extended infusions in the pediatric population. (Abstract No. 332). 2009 ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, FL, with a Pharmacodynamic Based Clinical Pathway for Empiric Antibiotic Choice in Patients Infected with Ventilator Associated Pneumonia. (Abstract No. 227). 2009 ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, FL, April 2009 270a. Crandon JL, Kim A, Nicolau DP. Tigecycline Penetration into the Epithelial Lining Fluid of Infected and Uninfected Murine Lungs. (Abstract No. 228). 2009 ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, FL, April 2009 Dr. David Nicolau's Scholarship 11/7/11 An In Vitro Pharmacodynamic Model of a Human Simulated High Dose, Prolonged Infusion Meropenem Regimen against Klebsiella spp. producing the KPC Carbapenemase. (Abstract No. 231). 2009 ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, FL, April 2009 and Anidulafungin (ANI) Given in Combination to Healthy Adults. (Abstract No. A1-423). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, (Abstract No. A1-011). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, Human Simulated Prolonged Infusion Doripenem against Pseudomonas aeruginosa. (Abstract No. A1-013). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, 12-15, 2009 Bulik CC, Nicolau DP. Doripenem (DOR) 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, September 12-15, 2009 276a. Bulik CC, JL. Pharmacodynamics (PD) of Pseudomonas aeruginosa 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, September 12-15, 2009 Nicolau's 11/7/11 92 No. D-721). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San September 12-15, 2009 278a. Koomanachai Evaluation of Tigecycline against Staphylococcus aureus in a Murine Pneumonia Model. (Abstract No. A1-552). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, Eagye KJ, Nicolau DP. Change in Anti-pseudomonal Carbapenem Susceptibility (ACS) in 25 Hospitals Is Not Associated with the Use of Ertapenem (ERT). (Abstract No. K-2061). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, Crandon JL, Kuti of Telavancin (TLV) and Vancomycin (VAN) against Methicillin Resistant Staphylococcus aureus (MRSA) with Ranging Vancomycin MICs in a Murine Pneumonia Model. (Abstract No. A1-1292). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009 281a. Stein GE, Smith C, Kepros J, Ji A, Nicolau DP, Dybas L, Saunders JP. Tigecycline Skin Penetration and Activity against Methicillin-Resistant Strains of Staphylococcus aureus (MRSA). (Abstract No. A1-554). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, Eagye KJ, Nicolau DP. Change in Imipenem (IMP) Susceptibility of Pseudomonas aeruginosa (PSA) in 24 Hospitals. (Abstract No. 863). 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 29 - November 1, 2009, Philadelphia, PA 2009 283a. Crandon JL, Sutherland C, Nicolau DP. Enhanced Room Temperature (RT) Stability of Doripenem (DOR) within Two Infusion Devices. (Abstract No. 220). 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 29 - November 1, 2009, Philadelphia, PA 2009 284a. Bulik CC, Christensen H, Nicolau DP. In Novel Cephalosporin, Against Resistant Phenotypes of Pseudomonas aeruginosa (PSA). Dr. David Nicolau's Scholarship 11/7/11 93 (Abstract No. 209). 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 29 - November 1, 2009, Philadelphia, PA 2009 285a. Crandon JL, Sutherland C, Nicolau DP. Doripenem remains stable up to 10 days under refrigeration and at least 28 days in the freezer. (Abstract No. 6-047). American Society of Hospital Pharmacists, 44th Annual Midyear Clinical Meeting, Las Vegas, NV, December 2009 286a. Crandon Dosing Regimens in Intensive Care Unit (ICU) Patients over Three Creatinine Clearance (CrCL) Ranges. (Abstract No. 248). Society of Critical Care Medicine's (SCCM) 39th Critical Care Congress, Miami, FL, January 2010 287a. Stein GE, Smith C, Kim G, Dybas L, Chung W, Nicolau DP. Evaluation of Serum Bacterial Kill of Moxifloxacin and Levofloxacin against S. pneumoniae Isolates with First-Step Mutations. (Abstract No. 10). National Foundation of Infectious Diseases, 2010 Annual Conference on Antimicrobial Resistance, Bethesda, MD, February 2010 288a. Ho VP, Nicolau DP, Dakin GF, Dosing for Surgical Prophylaxis in Morbidly Obese Patients. (Abstract No. O23). Surgical Infection Society, LAS Vegas, NV, April 2010 289a. Keel. RA, Kloft C, with Cystic Fibrosis. (Abstract No. A1-009). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010 290a. Keel. RA, Sutherland CA, Aslanzadeh J, Nicolau DP, Kuti JL. Correlation Between Vancomycin and MIC Values for Methicillin-Susceptible and -Resistant Staphylococcus aureus (MRSA) by Three Testing Methodologies. (Abstract No. D-162). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, September 12-15, 2010 291a. DP. Tissue Penetration and Exposure Profile of Tigecycline in Diabetic Patients with Wound Infections by In Vivo Microdialysis. (Abstract No. D1-026). 50th Dr. David Nicolau's Scholarship 11/7/11 94 Interscience Conference on Antimicrobial Agents and September 12-15, 2010 292a. Eagye KJ, Nicolau (ERT) Use and Anti-pseudomonal Carbapenem Susceptibility (ACS) in 25 Hospitals. (Abstract No. K-950). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010 vitro pharmacodynamics of pulmonary exposures of tigecycline alone and in combination with meropenem or rifampin against Klebsiella producing the KPC-2 carbapenemase. (Abstract No. A1-1147). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2010 294a. Bulik CC, Nicolau DP. In Vitro and In Vivo Efficacy of Human Simulated High Dose Prolonged Infusion Doripenem in Combination with Ertapenem against Carbapenemase-Producing Klebsiella pneumoniae. (Abstract No. A1-1386). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010 295a. Wiskirchen DE, Crandon JL, Williams No. A1-1380). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010 296a. DE, Crandon JL, Regimen Combined NXL104 No. A1-1379). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010 297a. Mazzei T, Breilh D, Kwa A, European and Asia-Pacific Hospitals. (Abstract No. A1-1387). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010 298a. Bulik CC, Tessier PR, Keel RA, Sutherland Efficacy of Human Simulated Piperacillin-Tazobactam David Nicolau's Scholarship Phenotypically Diverse Gram-negative Organisms. (Abstract No. A1-1381). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010 299a. Arya A, Banevicius MA, (Abstract No. F1-1628). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2010 300a. Eagye KJ, Nicolau DP. Comparing Single Dose in Colorectal Surgery: Agent Selection is Associated with Post-operative Infection. (Abstract No. K-1732). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September the PIRO Score for Predicting Intensive Care Unit Mortality in Patients with Ventilator Associated P. (Abstract No. K-2187). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, IBMP-10 Score for Predicting Mortality in Patients with Ventilator Associated P. (Abstract No. K-2189). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010 303a. Footer B, Patel G, Rubinstein E, Parish D, Nicolau DP, Paladino JA. If Pathogen Eradication Can Predict Clinical Outcome, Can Clinical Outcome Predict Pathogen Eradication? (Abstract No. L1-1753). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010 304a. from Intensive Care Units in European Hospitals: Results from the 2009 PASSPORT Program. (Abstract No. 1118). 23rd Annual Congress of the European Society of Intensive Care Medicine (ESICM), Barcelona, Spain, October 9-13, 2010 Concentration Dependent Protein Binding of Tigecycline in Adult Diabetic Patients. (Abstract No. 199). American College of Clinical Pharmacy, 2010 Annual Meeting, Austin, TX, October, 2010 Dr. David KJ, Nicolau Change in Imipenem Susceptibility of Pseudomonas aeruginosa in 25 Hospitals over 9 Years. (Abstract No. 3737). 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), October, Vancouver, British Colombia, Canada, 2010 307a. Keel RA, Zhanel G, Antimicrobials Gram-Negative Respiratory Isolates from Canadian Hospitals. (Abstract No. 3592). 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, British Colombia, Canada, October 2010 Antibiotics against Pseudomonas aeruginosa Isolates in USA Hospitals. (Abstract No. 2514). 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, British Colombia, Canada, October 2010 309a. Keel RA, Sutherland C, Crandon JL, Nicolau DP. Stability of Doripenem, Imipenem, and Meropenem at Elevated Room Temperatures. (Abstract No. 3-100). American Society of Hospital Pharmacists, 45th Annual Midyear Clinical Meeting, Anaheim, CA, December 2009 310a. Housman ST, Tessier PR, with Intravenous Drugs During Simulated Y-site Administration. (Abstract No. 3-206). American Society of Hospital Pharmacists, 45th Annual Midyear Clinical Meeting, Anaheim, CA, December in the ICU Anymore; Implications for Empirical Therapy. (Abstract No. 752). Society of Critical Care Medicine's (SCCM) 40th Critical Care Congress, San Diego, CA, January 2011 312a. Keel RA, Crandon JL, Nicolau DP. Efficacy of Human Simulated Ceftaroline Exposures against Phenotypically Diverse Staphylococcus aureus in a Mouse Thigh Model. (Abstract No. 1505). 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy, Milan, Italy, May 2011 313a. Wilde AM, Nailor MD, Nicolau DP, Kuti JL. Validation of a Ventilator Associated Pneumonia (VAP) Clinical Pathway using Quantitative Dr. David Nicolau's Scholarship 11/7/11 97 Bronchoalveolar Lavage (BAL) for Diagnosis. (Abstract No. 15). 29th Connecticut Infectious Diseases Society Meeting & Symposium, Yale University West Campus, Orange, CT, May Care Unit: A Pharmacodynamic Approach to Increasing Quality of Care. 2011 EPS Montreal International Clinical Medicine Forum, Montreal, Quebec, Canada, June 2011 315a. Hagihara M, Wiskirchen DE, Kuti JL, of Vancomycin (VAN) and Cefazolin (CFZ) Alone and in Combination against Various Methicillin-Resistant Staphylococcus aureus (MRSA). (Abstract No. A2-025). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011 Administered as an Intravenous (IV) Bolus versus Standard 30 Minute Infusion. (Abstract No. A2-565). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011 317a. Housman ST, Pope JS, Disposition of Torezolid Following 200mg Oral Torezolid Phosphate in Healthy Volunteers. (Abstract No. A1-1747). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011 318a. Housman ST, Sutherland CA, Nicolau DP. In Vitro Activity of Six Novel Compounds Against Selected Resistant Phenotypes of Pseudomonas aeruginosa. (Abstract No. F1-1849). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011 319a. Housman ST, Keel RA, Crandon JL, Williams G, Nicolau DP. Efficacy of Human Simulated Exposures of Ceftaroline Fosamil Against Phenotypically Diverse Enterobacteriaceae. (Abstract No. A2-558). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 2011 320a. Keel RA, Crandon JL, of Linezolid in Three Murine Models. (Abstract No. A1-1746). Dr. David Nicolau's Scholarship 11/7/11 98 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011 (DOR) by Traditional or Prolonged Infusions (PI) in Patients with Serious Infections. (Abstract No. A2-566). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011 322a. Goff DA, Nicolau DP. imipenem, meropenem to aeruginosa (Abstract No. XX-XXX). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011 323a. Housman ST, Sutherland CA, Nicolau DP. In Potency of Rib-X Novel Compounds against Respiratory Pseudomonas aeruginosa isolates. (Abstract No. XXX). 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, Ma, October 20-23, 2010 324a. Wilde AM, Nailor MD, Nicolau DP, Kuti JL. Decreased Compliance of a Ventilator Associated Pneumonia (VAP) Clinical Pathway Results in Inappropriate Antibiotic Utilization and Increasing Mortality. (Abstract No. XXX). 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, Ma, October 20-23, a Resistant Population of Clinical Pseudomonas aeruginosa (PSA) Isolates. (Abstract No. 858). 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, Ma, October 20-23, 2010 326a. Leung AK, Nicolau DP, DiPersio JR, Pasquale TR. Antimicrobial Therapy Optimization by Institute-specific Pharmacodynamics Profiling. (Abstract No. XXX). 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, Ma, October 20-23, 2010 "}